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Thesis Summary 
Background: The number of lymph nodes (LN) harvested following colorectal 
cancer (CRC) resection is important for accurate LN stage discrimination and 
has been considered as a quality marker in the surgical treatment of CRC.  
Stage discrimination is critical to ensure that patients receive the optimal 
treatment for their disease stage and to provide prognostic information for the 
patient.   
Aims:  To identify factors that independently predicted LN harvest (LNH), 
study the impact of national guidelines and audit had on LNH at national level 
and to examine the impact that LNH has on survival of node negative and 
node positive CRC.   
Methods:  Data on patients having CRC resection at unit and national level 
were studied, and multivariate statistical modelling used to determine 
independent predictors of harvest and survival. 
Results:  
 The reporting pathologist is an independent variable for LNH 
 The operating surgeon did not influence LNH  
 Inter unit variability in LNH exists 
 National audit against national standards improved nodal yield at a 
national level   
 Increasing LNH independently predicted survival in Dukes’ stage B 
CRC, up to a level of 15 nodes per patient.   
 Lymph node ratio (LNR) independently predicted survival in Dukes’ C 
CRC and may be a more sensitive prognostic indicator than current 
lymph node staging systems.   
Conclusions: The principal conclusions of this thesis were that LNH is an 
appropriate quality indicator of combined pathological and surgical activity, but 
not surgery in isolation.  National audit against national guidelines has 
improved LNH in Wales.  Survival differences in node negative CRC up to a 
level of fifteen nodes suggests that the current national guidelines of twelve 
nodes per patient should be increased.  LNR was found to predict survival in 
CRC patients suggesting it might be appropriate to include LNR in future 
staging systems for CRC.   
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Recommendations arising from the findings of this thesis 
 
 The use of lymph node harvest as a marker of quality in colorectal 
cancer treatment is appropriate for combined surgeon and pathologist 
performance, but not surgical performance in isolation. 
 In addition to participation in national audits, multi-disciplinary teams 
treating colorectal cancer should perform clinician identifiable intra-unit 
risk adjusted audit of the lymph node harvests of its surgeons and 
pathologists. 
 The current Association of Coloproctology of Great Britain and Ireland 
model for risk adjusting lymph node harvest is calibrated too low and 
should be revised in line with contemporary data.  
 The current twelve-node national harvest guidance for lymph node 
retrieval following colorectal cancer should be revised to a higher level 
and take into account differences in harvest according to tumour site. 
 National audit against recommended national performance guidelines 
can be expected to improve adherence with the prescribed guidelines. 
 In node negative colorectal cancer at least fifteen nodes should 
routinely be evaluated, to maximise confidence in staging 
 Patients assigned a node negative status following examination of less 
than twelve nodes should be considered for adjuvant chemotherapy. 
 Lymph node ratio should be incorporated into staging systems for 
colorectal cancer and patients with high lymph node ratio levels may be 
targeted for a more aggressive chemotherapy policy. 
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0.1  Introduction and Literature Review 
 
Colorectal cancer (CRC) is the third most common cancer in the United 
Kingdom with over 37,000 new cases registered annually.  During the last 
decade its incidence has remained relatively static but there has been a 16% 
improvement in age-standardised mortality. Even with this improvement there 
were over 16, 000 deaths from colorectal cancer in the United Kingdom in 
2007[1]. 
 
The improved survival has been achieved through advances in several areas, 
including staging, MDT working, surgery, pathological reporting and also 
oncological treatments.  Progress in medical oncology has been achieved 
through both advances in the efficacy of adjuvant chemotherapy and 
improved accuracy of disease staging, that identifies the patients who may 
benefit most from adjuvant treatment. 
 
In the United Kingdom the two most commonly used staging systems for CRC 
are those of Dukes’ and the Union for International Cancer Control (UICC) 
Tumour, Node, Metastases (TNM) classification systems[2, 3] (see appendix 
1 and 2).  The identification of lymph node metastases is central to both these 
CRC staging systems and has been integral to most                                                                                                                                                                                                                                                                                                                                                                                                
staging systems since 1932 when Cuthbert Dukes modified his initial 1929 
staging system to the following[2, 4], 
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“ A cases are those in which the carcinoma is limited to the wall of 
the rectum, there being no extension into the extrarectal tissues 
and no metastases in lymph nodes, B cases those in which the 
carcinoma has spread by direct continuity to the extrarectal tissues 
but has not yet invaded the regional nodes, and C cases those in 
which metastases are present in the regional lymph nodes[2]” 
 
This modification arose from survival analysis of patients with rectal cancer 
treated by surgical excision.  It was noted that patients classified as Dukes’ C 
under the new modification had a 3 year survival of 7% against 73% for 
Dukes’ B and 80% for Dukes’ A[2].   
 
Although Dukes’ initial staging system pertained to tumours of the rectum 
there have been a number of modifications since, including its use for colonic 
as well as rectal cancer[5].  Throughout these modifications metastatic 
involvement of regional lymph nodes has remained a critical feature.  
Similarly, the UICC TNM system also clearly identifies patients in whom there 
is lymph node involvement (detailed in appendix 2).  The reason that nodal 
involvement remains such a crucial feature is its impact on a patient’s 
likelihood of long-term cure, lymph node involvement confers a reduction in 5 
year survival of 20-30%[1, 6], (see table 0-1 below).  Consequently the 
presence of lymph node metastases usually modifies the therapeutic 
recommendation for a patient. Node positive patients may be offered adjuvant 
chemotherapy, with the expectation of a 10-15% survival benefit[7].  
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Table 0-1 – Percentage of cases and 5 year survival by Dukes’ stage at 
diagnosis, colorectal cancer patients diagnosed 1996-2002 England[1] 
 
Dukes’ Stage at 
Diagnosis 
Percentage of Cases 5 Year Relative 
Survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% 6.6% 
Unknown 34.3% 35.4% 
 
 
Accurate nodal stage discrimination is also important to provide patients with 
realistic and accurate estimates of prognosis and to allow meaningful 
comparative audit of outcomes between individual units.  It has been shown 
that the number of lymph nodes harvested from a case of CRC may have an 
important role in accurate nodal stage discrimination[8-19].   If too few nodes 
are sampled it is possible that a case in which lymphatic metastases are 
present, although not identified, may inaccurately be assigned a node 
negative status.  The consequence of which is under treatment and 
inaccurate prognostic information provided to the patient.  At a unit or 
population level this may also worsen stage specific survival results through a 
phenomenon called stage migration, which has previously been described by 
Feinstein[20] 
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0.2  Stage Migration – The Will Rogers’ Effect 
 
“When the Okies left Oklahoma and moved to California, they raised the 
average intelligence level in both states.”  
Will Rogers 1930 
 
Feinstein first proposed an apparent linkage between the American Humorist 
Will Rogers and the importance of accurate stage discrimination on improving 
survival in stage specific cancer in 1985[20].  Feinstein’s work identified that 
advances in diagnostic imaging in lung cancer patients improved staging by 
identification of metastatic disease, which lead to an improved survival in all 
‘TNM’ groups; the relevance in CRC patients relates to lymph node status.  In 
a unit where lymph node harvest is optimised, it is more likely that patients will 
accurately be staged if node positive.    
 
This improved stage discrimination could have the effect of improving stage 
specific survival of both node negative and node positive groups. If the node 
negative group includes patients falsely assigned to this stage (through failure 
to identify present nodal metastases), these patients are likely to worsen the 
overall stage specific survival of this group. The addition of these patients to 
the node positive stage may also improve the stage specific survival of this 
group.  This is because these patients are more likely to have a lower burden 
of nodal disease, with associated improved survival, compared to patients 
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assigned to the node positive stage who may have more advanced lymphatic 
involvement.  
 
 
0.3  Is the Number of Lymph Nodes Harvested Important? 
 
If no lymph nodes are evaluated following surgical resection of bowel cancer, 
it follows that this case can never be assigned a node positive status.  It is 
less clear on the other hand whether there are a critical number of nodes that 
should be examined to be certain of identifying all node positive cases.  There 
has never been, nor is there likely to be, a randomised control trial evaluating 
the association between lymph node examination and survival after the 
surgical treatment of CRC.  The highest quality available data is from two 
secondary analyses of multicentre randomised control trials of adjuvant 
chemotherapy focusing on the impact of lymph node harvest on survival[10, 
21].  A summary of the results of these studies is presented in table 0-2, 
which shows that increasing nodal harvest is associated with improved 
survival.  
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Table 0-2 – Five year survival and disease free survival from secondary 
analyses of adjuvant chemotherapy RCT’s  
 
Study 
 
Nodal 
Status 
No 
Lymph 
Nodes 
Overall 5 
year 
Survival % 
p  
value 
Disease 
Free 
Survival % 
p 
value 
  <11 73  72  
Intergroup 0089[10] N0* 11-20 80 <0.001 79 0.11 
(n = 3411 patients)  >20 87  83  
  <11 67  65  
 N1* 11-40 74 <0.001 70 <0.001 
  >40 90  93  
 N2* 1-35 51 0.002 48 0.014 
  >35 71  69  
 Combined 0-7 69  56  
INTACC[21] N0* &  8-12 69 0.031 60 0.002 
(n=3248 patients) Node 
positive 
13-17 76  64  
  >17 76  67  
  0-7 81  66  
 N0* 8-12 81 <0.001 74 <0.001 
  13-17 87  77  
  >17 89  83  
  0-7 57  47  
 Node 
positive 
8-12 59 0.3 48 0.11 
  13-17 66  53  
  >17 63  54  
*N stage according to TNM staging system.  p values = log-rank test 
 
The intergroup 0089 study[10] examined differing adjuvant fluoracil based 
chemotherapy regimens for high risk colon cancer patients, high risk was 
defined as node positive or node negative with the primary tumour invading 
the serosa or  with obstruction or perforation.  Rectal cancers were excluded.  
There were 3411 patients studied of whom 648 were node negative. The 
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principal finding, of this secondary analysis, was that survival was improved in 
both node negative and node positive colonic cancer as more lymph nodes 
were examined.  The authors used recursive partitioning to identify the 
breakpoints used in their survival analysis.  This demonstrated that in node 
negative cases survival improved unto a level greater than 20 nodes.  In node 
positive disease survival improved until >40 nodes were examined in stage 
N1 disease and until >35 nodes were examined in stage N2 disease.      
The second secondary analysis of the INTACC study [21] was a study of 
differing adjuvant fluoracil based chemotherapy regimens for patients with 
high risk colon cancer.  High risk in this study was defined as node positive or 
node negative with the primary tumour invading the serosa.  Again rectal 
cancers were excluded.  The study population was 3248 patients, of whom 
1635 were node negative and 1613 were node positive.  In this study the 
breakpoints for lymph node harvest were based on quartile division of lymph 
node harvest of the whole study population.  The principal finding of this 
secondary analysis was that survival of node negative cancer was dependent 
on lymph harvest, although in this study the number of lymph nodes 
harvested did not impact on survival of node positive disease. 
 
Apart from these secondary analyses of randomised controlled trial (RCT) 
data there have been several population based cohort studies and single 
centre series that have studied the impact of nodal harvest on survival, 
selected results are presented in table 0-3.  A study by Cserni et al[13] of 
8574 node negative patients has not been presented in the table because 
their results were not suitable for tabulation.  In this study data from the 
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Surveillance, Epidemiology and End Results Program (SEER) was subjected 
to multi-variate proportional hazards modelling to investigate impact of the 
number of nodes examined on survival.  It was found that survival improved 
with increasing nodal harvest and that there was no cut off above which an 
increase in the number of nodes evaluated had no effect on prognosis.  
Another national cohort study by Vather et al.[19] has also not been tabulated 
due to the number of subgroups in their results.  This study used New 
Zealand Cancer Registry data from 4309 patients with colonic cancer.  Vather 
and colleagues divided both node negative and node positive patients into 
stratum of 4 node intervals up to >33 nodes (harvest = 1-4 nodes ,5-8 nodes 
,9-12 nodes etc).  A stepwise improvement in survival for both node negative 
and node positive cancer up to a level of 13-16 nodes was observed; beyond 
this level survival was similar irrespective of the number of nodes examined.  
Although both node negative and node positive groups exhibited improved 
survival up to the 16-node level the differences in survival between strata 
were more marked in the node negative than positive group.  A British 
population based study of 3592 CRC patients by George and co-workers[22] 
similarly found that survival improved for both node negative and node 
positive disease with increasing nodal harvest, with nodal harvest stratified 
into three groups of 0-4 nodes, 5-10 nodes and >10 nodes. 
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Table 0-3.  Impact of nodal harvest on survival in population based 
cohort studies and single centre series. 
Study Number of 
patients 
Nodal 
Status 
No Lymph 
Nodes 
Overall 5 year 
Survival  
p  value 
   1-7 49.8%  
National Cancer  35 787 N0* 8-12 56.2% <0.001** 
Database, USA[11] Colonic only  >13 63.4%  
Swedish Cancer 
Registry[15] 
 
3735  
 
N0* 
 
1-11 
 
65% 
 
<0.001 
 Colonic only  >11 75%  
Kentucky cancer 
Registry[23] 
 
2437 
 
N0* 
 
1-12 
 
56% 
 
<0.001** 
 Colorectal  >12 63%  
  N0 <7 49%  
Caplin et al[14] 222  >7 68% 0.001** 
 Colorectal N1 <7 NA  
   >7 NA 0.7** 
Law et al[24] 115 N0* <7 62%  
 Colonic only  >7 86% 0.03** 
Cianchi et al[17] 140 N0* <9 54.9%  
 Colorectal  >9 79.9% <0.001** 
   <7 62%  
Goldstein et al[9] 745 N0* 8-12 68% 0.018** 
 Colorectal  13-17 71%  
   >18 76%  
  N0 11.4 83%  
Ratto et al[12] 487  29.4 91% 0.04*** 
 Colorectal N1 11.4 58.9%  
   29.4 84.2% 0.06*** 
  N0 0-11 77%  
Edler et al[16] 1025  >12 88% 0.02** 
 Colorectal N1 0-11 54%  
   >12 66% 0.08** 
* Impact on node positive patients not studied ** log-rank test  
*** log-rank test, study compared different pathological techniques for lymph node evaluation 
with overlapping time periods, mean lymph node harvests according to technique were 
compared  
 
The findings from the two secondary RCT analyses[10, 21] mirror the results 
of the majority of the population based studies and single centre series 
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previously discussed, in that nearly all studies have demonstrated a survival 
advantage with increased harvests in node negative disease.  However, the 
situation in node positive cancer is far less clear with some studies 
demonstrating a survival advantage with increased harvests and others 
showing no difference.   
 
In node negative patients it is plausible that stage migration alone could 
explain the improved survival observed with higher nodal harvests.  However, 
stage migration alone cannot explain the better survival observed by some in 
patients with node positive disease who have higher nodal yields.  It is 
possible that a more radical lymphadenectomy or tumour-host interaction may 
play a role in these patients.  If the host patient is able to mount a significant 
immune response to the disease process there maybe reactive 
lymphadenopathy that makes lymph node identification easier.  The 
consequence of which is that overall harvest improves because the nodes are 
easier to identify.  This ability to mount an immune response may then confer 
a survival benefit because it signifies that the host is better able to fight off the 
disease process.  In a recent cohort study evaluating relationship between 
node number and survival in colon cancer patients, patients with prominent 
lymphocytic infiltration in the primary tumour had a survival advantage; these 
patients also tended to have higher nodal counts[22].   
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0.4  What is an appropriate nodal harvest? 
 
The body of published literature thus supports the view that increasing nodal 
harvest may optimise staging and possibly survival in the treatment of CRC.  
However, there is controversy in the scientific literature concerning how many 
nodes need to be evaluated in order to minimise the risk of under staging a 
patient’s disease.  Published recommendations range from a minimum of six 
nodes[14] to as many as possible[9, 13]. Following a review of the published 
evidence at that time (1990) the Working Party Report to the World Congress 
of Gastroenterology recommended that at least 12 nodes per patient need to 
examined following CRC excision[25].  This recommendation of 12 nodes has 
subsequently been endorsed by National agencies in both the United 
Kingdom and the United States of America[26-29].  In spite of these 
endorsements there is a lack of agreement as to whether obtaining increased 
nodal harvests actually improves outcomes[30] and whether the 12 nodes 
guidance is appropriate[21]. 
 
0.5  Factors Influencing Lymph Node Harvest 
 
There are several factors that influence the absolute number of lymph nodes 
examined following surgical resection of CRC.  These relate to the individual 
techniques of the surgeon and pathologist and factors that relate to the 
patients biological make up, tumour biology and type of surgical resection[31, 
32].  The number of nodes present in any one patient’s specimen is fixed, 
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however, whether they are removed or identified is reliant on the surgeon and 
pathologist involved in the care of that patient.  
 
0.6  The Surgeon and Pathologist as Variables in Lymph Node Harvest 
Anatomical teaching is that the lymphatic drainage of the gastrointestinal tract 
lies adjacent to its arterial supply. In the large intestine there are three 
recognised groups of nodes that drain the bowel: paracolic nodes adjacent to 
the bowel, intermediate nodes that lie along the main blood vessels supplying 
the colon and along the marginal artery and finally pre-aortic nodes (see 
figure 0-1).  It is believed that the nodal basins drain into each other from 
below upwards in a sequential manner[33].  Surgical dictum has been to 
achieve a high proximal ligation of the principal vascular pedicle supplying the 
area of bowel in which a tumour is located [34].  This maximises nodal 
clearance and provides prognostic information because involvement of the 
apical nodal confers a worse prognosis[35].   It therefore follows that a less 
radical surgeon who fails to achieve as high a tie as possible is likely to 
provide a reduced yield.  Following resection lymph node identification 
becomes the responsibility of the reporting pathologist.  
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Figure 0-1 The lymphatic nodes of the colon and rectum[36] 
 
 
 
Inter-unit variation in the number of nodes examined following CRC resection 
is commonly reported [15, 37-45].  Different patient populations with differing 
pathological stage of disease treated could explain this inter-unit variation.  
However, comparative audit between units in close geographical proximity, 
managing similar disease profiles have demonstrated that significant 
difference between units remains[39, 46].  The implication of this finding is 
that differences observed, in these studies at least, must be attributable to the 
techniques of surgeon or pathologist or both, rather than intrinsic differences 
in the patients treated.  Whilst inter-unit variation in lymph node harvest is 
frequently reported, studies examining the impact that individual surgeon and 
pathologist has on lymph node harvest are less frequent.   
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Looking specifically at the surgeon’s role, it is a reasonable assumption that 
the radicality of surgical excision will have an impact on the available number 
of nodes in a specimen; if just the bowel alone, without any attached 
mesenteric tissue is submitted for examination then the nodal harvest is likely 
to be low.  Some of the available literature supports the supposition that 
surgical performance contributes the number of nodes harvested; with the 
finding that two factors, higher surgeon volume and coloproctology sub-
specialisation, are associated with a higher nodal harvest[47, 48].  However, 
these data emanate from the United States of America (USA), published 
United Kingdom (UK) data has found that a sub-specialist interest in 
coloproctology does not impact on lymph node harvest.  Norwood et al 
published their experience in Leicester and found that the operating surgical 
team (colorectal specialist versus general surgeon) made no difference in the 
nodal harvest of 2449 patients operated on over a nine year period in their 
unit[49].  Another small UK series of 167 rectal cancers, in which non-
specialist colorectal surgeons performed 21% of resections, found no 
difference in lymph node harvest between surgeons[50].  Another difference 
between the UK and USA is that sub-specialisation in colorectal surgery has 
occurred more rapidly in the UK, where a specialist colorectal surgeon now 
carries out almost all elective CRC resections.  This specialisation would be 
expected to confer less variability in the radicality of mesenteric excision and 
therefore there should be less variability in the lymph node harvest achieved 
by colorectal sub-specialist surgeons.  
 
 31 
Whilst it is believed that the extent of mesenteric resections performed in the 
UK are fairly standardised, the work of Hohenberger and colleagues in 
Erlangen, Germany, using a technique of, “complete mesocolic excision 
(CME)” has demonstrated that it is possible to achieve a more radical 
lymphadenectomy than is the current norm in the UK [51, 52].  Hohenberger 
et al. have been using the more radical CME for over 20 years and recently 
reported their results, in brief, the technique requires complete mobilization of 
the entire mesocolon, and high central vascular ligation[51].  Using this 
technique they have a median nodal harvest of 29 nodes per patient.  The 
Erlangen group has recently performed a comparative study of their post-
operative specimens against those following surgery in Leeds[52].  This study 
found that specimens removed in Erlangen had higher lymph node harvests 
(median lymph node harvest 30 in Erlangen versus 18 in Leeds), had greater 
mesenteric volume with a longer length of the central vascular pedicle and 
had longer colonic segments compared to the colorectal unit in Leeds, 
UK[52].  In this study survival was not an outcome measure, however, they 
have previously reported that their five year survival using CME is much 
higher than is observed in the UK[1], with a five year survival of 90% for stage 
I and II disease and over 70% for stage III disease[51].  These results 
demonstrate that more radical surgery can be expected to achieve higher 
lymph node harvests, provided the extra nodes resected are identified in the 
pathological examination of the specimen.  
 
The impact that individual pathologists have on nodal harvests has been 
infrequently reported.  However, whilst there is a relative paucity of published 
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research, it again seems reasonable to assume that the pathologist should 
play a significant role in the number of nodes identified from any one 
specimen.  The literature that is available supports this hypothesis.  Rieger et 
al, in a single surgeon series working at two separate Australian hospitals 
concurrently, found that the harvest achieved was significantly different at the 
two sites, in unit 1 (76 specimens) the median harvest was 10 nodes/patient 
and in unit 2 (54 specimens) 18 nodes/patient [42], the case mix in this series 
was similar suggesting that the difference must relate to the reporting 
pathologist or pathological technique.  Recent data from the Dutch rectal 
cancer radiotherapy randomised trial of 1227 patients, found large differences 
in nodal yields between different units and between pathologists within a 
single unit with similar disease profiles[38].  In a smaller UK single unit study, 
of 167 rectal specimens[50], differences between pathologists were reported 
that was significant on both uni and multivariate analysis.  Johnson et al [47], 
in addition to finding that surgeon volume impacted on harvest, also found 
that specimens that underwent gross examination by a staff pathologist had 
more nodes identified than those examined by residents or staff technicians. 
Ostadi et al [53], in a small single centre series of 264 patients, reported that 
multi-variate analysis of factors affecting lymph node harvest showed the 
pathology assistant to be the most important determinant of lymph node 
harvest.  The mean number of nodes retrieved between assistants in this 
series ranged from 12.6 to 29.7 (p<0.001).  Whilst the identity of the pathology 
assistant appears important in studies from the United States, this is less 
likely to have an impact on United Kingdom results because most specimen 
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dissection is carried out by medically qualified pathologists rather than 
technicians.  
 
0.7  Pathological Techniques to Increase Nodal Yield 
 
Most laboratories in the UK use a manual dissection technique to identify 
lymph nodes, as outlined in the Royal College of Pathologists guidance on 
reporting colorectal cancer, “Standards and Datasets for Reporting Colorectal 
Cancer (2nd edition) 2007” [28].  In summary, this recommends that nodal 
identification should begin with the apical node, identified by serial sectioning 
from the sutured vascular margin.  The remaining nodes are identified by 
transverse slicing of the mesentry following adequate fixation.  The 
recommendation also highlights that although a standard of 12 nodes has 
been set, this does not mean that pathologists should stop searching once 
twelve nodes are identified.  This technique has been reported to be laborious 
and time consuming and is often delegated to a trainee pathologist, with 
limited experience[54].  
 
Compared to manual dissection the technique of chemical fat clearance has 
been reported to increase nodal yield [32, 48, 55-59] and upstage tumours[32, 
56, 58-60].  Chemical fat clearance involves chemical dissolution of the fat in 
the mesentry in which the nodes are embedded.  Haboubi et al. [56] subjected 
47 colorectal resection specimens to standard laboratory processing, followed 
by alcohol / xylene clearance and found that an additional 51.5 nodes / 
specimen were identified.  This resulted in 12 out of 41 malignant cases being 
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upstaged.  Brown et al [59] subjected 15 colonic specimens to serial 
dehydration in alcohol and acetone.  They found that the nodal harvest rose 
from 20.8 to 68.8 nodes/patient, 83% of the additional nodes were <2mm.   In 
this series finding the additional small nodes did not upstage any tumours 
from N0 to N1/2, however, three stage N1 cases were upstaged to N2 
disease.  Although finding the extra small nodes did not change any patients 
from a node negative to node positive stage in this series, it has previously 
been recognised that small nodes can harbour metastatic disease.   Herrera-
Ornelas et al. [61] found that 39 of 59 metastatic nodes were <5mm in size.  
Although some authors disagree [62],  the consensus of the literature 
supports the view that fat clearance techniques will up-stage some tumours.  
The reasons why this technique have not been universally adopted are not 
clear but may be due to the associated extra-workload for the pathology 
laboratory[54].   
 
0.8  Sentinel Node Biopsy 
 
Since sentinel lymph node biopsy (SLNB) was first described in the treatment 
of malignant melanoma[63], it has become the norm in the management of 
many solid organ malignancies, particularly breast cancer and malignant 
melanoma [64, 65].  In these tumours, prior to SLNB introduction, the 
conventional surgical treatment was usually wide local removal of the primary 
tumour and a full lymphadenectomy of the primary draining nodal basin, 
whether or not these nodes contained metastatic disease. The sentinel lymph 
node (SLN) concept states that the first lymph node or nodes to receive direct 
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drainage from a tumour will be the first site of metastatic spread, as such if 
this node is free of metastatic tumour the remainder of the nodal basin will 
also be free of disease. In breast and melanoma surgery SNs are identified in 
the lymphatic basin by injection into or near the tumour of either or both 
aqueous blue dye and radiolabelled colloid (identified using a gamma probe).  
This is performed at the time of resection of the primary tumour.  The 
identified SN is then surgically removed and subjected to histopathological 
assessment. If the SNs are found to be metastatic, the patient has a second 
operation to clear the nodal basin.  If however, the SN is free of disease, the 
patient is spared the unnecessary morbidity of a full surgical 
lymphadenectomy. The potential benefits of the technique for node negative 
patients with breast cancer and melanoma are therefore clear and the 
technique has been validated as an effective and oncologically sound 
technique[66, 67].   
 
Previous authors have explored the use of both in vitro and ex vivo sentinel 
node biopsy in the management of colorectal cancer, [68-72].  The results of 
in vitro sentinel node biopsy have been mixed with a few reporting excellent 
results[69], whilst others have experienced several difficulties, including:  
failure to identify the sentinel node/s in up to 40% of patients[73], false 
negative rates of up to 67%[74] and sensitivities as poor as 25%[75].  The 
reasons for these difficulties are probably multi-factorial but include the 
relative variability in lymphatic drainage of the colon and rectum, compared to 
other solid organ cancers in which in vitro sentinel lymph biopsy use has been 
successful.  Another problem with the technique in the management of 
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colorectal cancer is that “skip lesions”, in which the nodes closest to the 
primary tumour are negative but distant nodes are metastatic, appear to occur 
more frequently than in other solid organ malignancies[76, 77].  In addition, 
the anatomy of the arterial supply to the large bowel lends itself to a 
standardised lymphadenectomy, whether or not nodes are involved.  It would 
be inappropriate and technically challenging to re-operate on a patient shortly 
after an initial large bowel resection in order to perform a more radical 
mesenteric excision because a sentinel node has been found to be positive.  
For these reasons the usefulness of in-vitro sentinel node techniques must be 
questioned.  
 
The use of ex-vivo sentinel node biopsy appears to have more promise, this is 
primarily because it does not alter the therapeutic treatment of the patient (the 
extent of surgical lymphadenectomy remains unchanged) but does allow for a 
more focused assessment of the sentinel node [68, 70, 72, 78], including 
using techniques such as ultra-sectioning, immunohistochemistry or RT-PCR 
analysis [54].  The use ex vivo mapping in this way has been shown to 
upstage up to 30% of patients initially assigned a N0 status to N1 or N2 stage 
disease[79, 80].  With the use of ex-vivo sentinel node biopsy, similar rates of 
technical failure to those of in-vitro biopsy have been observed[68, 78, 81], 
however, those patients in whom the technique fails can still have a 
conventional pathological assessment of their nodal basin.  
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0.9  The Patient as a Variable on Lymph Node Harvest 
 
Lymph node harvest achieved following bowel cancer resection appears to be 
dependent on both the techniques of the surgeon and the pathologist.  
However, even if both optimise their technique is there inter patient variability?  
A large number of variables that relate to the patient have been purported to 
influence nodal yield.    Patients presenting with bowel cancer will have 
differing demographic profiles and biological make up, differing disease 
stages and possibly have received differing pre-operative neoadjuvant 
treatments, all of these may impact on the numbers of nodes evaluated 
following colorectal resection. 
 
The impact of patient gender on lymph node harvest has been studied, with 
mixed results [19, 40, 44, 49, 50, 53, 82-85].  Some studies have reported a 
statistically significant difference between the sexes, with all studies that 
identified a difference reporting that yields are higher in women than in 
men[19, 44, 53, 84, 85].  Conversely, there are several studies that have not 
reported a significant difference between the sexes [40, 49, 50, 82, 86].  
Critical appraisal of the methodology of these studies, shows that the larger 
series of national cancer registry data, with between 4500 and 116000 
patients, [19, 44, 85] have found that bowel cancer resection in women 
confers a higher nodal harvest.  The majority of studies which refute this 
finding are single centre studies with a maximum of 2500 patients, the 
exception being the analysis of ACPGBI bowel cancer audit data with eight 
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thousand patients[40] that demonstrated no difference.  The finding that the 
larger studies are those with a statistical difference raises the possibility that 
there could be a type I error.  Even if this is not a manifestation of a type I 
error, although statistically significant differences have been reported, the 
actual increased harvest reported in women ranges between 0.4 and 1 node 
per patient, which must be considered of doubtful clinical significance[19, 84]. 
 
Most studies that have examined whether patient age influences lymph node 
yield have found that advancing age confers a reduced lymph node yield 
following colorectal resection [38, 40, 48, 49, 53, 82].  The way in which these 
differences have been analysed and reported in the literature varies:  some 
studies have carried out categorical analysis, with patients age split by 
decades [44, 48, 87], all three of these studies reported an increased yield of 
three or four nodes in patients under the age of fifty, but less marked 
reductions between subsequent decades of between zero and one node per 
increased decade.  Tekkis et al looked at the impact of age on harvest in 
patients reported to the ACPGBI bowel cancer audit using regression 
analysis, finding that every advancing decade conferred a reduction in harvest 
of 0.9 nodes/decade[40]. Similarly, Norwood et al in a series of 2449 patients 
from Leicester subjected their data to linear regression analysis, finding a 
reduction in harvest of one node for every advancing decade using linear 
regression analysis [49].  Whilst there is heterogeneity in the methods used in 
the above analyses, the homogeneity of the results strongly supports 
increasing age is associated with a reduced lymph node harvest.  
Explanations for this include the possibility that surgeons are more likely to 
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perform a wider lymphadenectomy in young, fit elective patients[40] or 
alternatively lymph nodes may involute with  advancing age[88]. 
 
In the literature patient gender and age are the most frequently reported 
patient related variables that may impact on lymphatic harvest.  Relatively few 
other patient related variables have been studied. Patient race has been 
examined, with the finding that it has no impact on harvest [44, 49, 82].  Body 
Mass Index (BMI) has also been evaluated, but only in studies limited to rectal 
tumours.  Mekenkamp et al in a secondary analysis of the Dutch multi-centre 
radiotherapy rectal cancer found that higher BMI conferred a reduced 
harvest[38].   Ha et al in a smaller single centre series of rectal cancers 
reported that both low and high BMI reduced nodal yield[84].  In the only study 
that had addressed whether patient co-morbidity impacted on nodal yield, 
Tekkis et al. found that following multi-variate analysis patients with higher 
American Society of Anaesthesiologists (ASA) score (worse co-morbidity) had 
lower nodal yields than those classified as ASA I (see appendix 3 for 
definitions of ASA).   
 
0.10  Tumour Stage and Size and Nodal Harvest 
Studies that have examined whether disease stage impact on lymph node 
harvest have found that more advanced tumours, both in terms of stage and 
size of tumour, are associated with increased lymph node harvests[38, 40, 48, 
50, 53, 82-84, 86, 87, 89].  The staging methods reported in these studies 
have been heterogeneous, with some studies using T and N staging [38, 48, 
82, 86, 89] whilst others have used either the Dukes’ system [40, 50] or the 
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AJCC system[53, 84].   Table 0-4 (page 40) summarises the findings of 
studies that have reported their results regarding lymph node harvest and 
pathological stage.  All studies presented have found statistically significant 
differences in yield yields according to disease stage using multi-variate 
analysis techniques.  The table only includes results suitable for presentation 
in a tabulated format (some published series have reported their results in 
graphical format not suitable for summarisation in this manner).  
 
In addition to pathological stage, tumour size has also been found to 
independently affect lymph node harvest.  Chou and colleagues, in the largest 
reported study of factors impacting on harvest, reported that for every 1cm 
increase in tumour size a 2-3% increased yield was observed [82].  Data from 
the Dutch rectal cancer radiotherapy found that harvests increased by 3 
nodes between tumours measuring <2cm and 2-5cm and by a further 3 nodes 
from 2-5cm and >5cm [38].  Rullier et al. in a smaller single centre study of 
factors impacting on harvest in rectal cancer specimens found that splitting 
specimens into those with a primary tumour less than 4cm in size and greater 
than 4cm conferred an increase in yield of 6 nodes (median 12 versus 18 
nodes respectively)[83].   
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Table 0-4 Summary of effect of pathological stage on lymph node 
harvest in published series 
 Staging System Reported 
 
Study T stage N stage Dukes’ AJCC 
 
Chou et al.[82]* 
(n = 153 483) 
Colon 
T1 - 6 nodes 
T2 - 10 nodes 
T3 - 12 nodes 
T4 - 11 nodes 
Rectal 
T1 - 5 nodes 
T2 - 8 nodes 
T3 - 10 nodes 
T4 - 8 nodes 
Colon 
N0 – 10 
N1 – 12 
 
 
Rectal 
N0 – 8 nodes 
N1 – 11 nodes 
Not reported Colon 
I - 9 nodes 
II - 11 nodes 
III - 12 nodes 
Rectal 
I - 8 nodes 
II - 9 nodes 
III - 11 nodes 
Baxter et al.[44]* 
(n= 116995) 
Not reported Not reported Not reported I – 6 nodes 
II – 10 nodes 
III – 11 nodes 
Elferink et al.[87] 
(n=10788) 
Node negative 
T1 – 5 nodes 
T2 – 7 nodes 
T3 – 9 nodes 
T4 – 8 nodes 
Node positive 
T1 – 5 nodes 
T2 – 8 nodes 
T3 – 9 nodes 
T4 – 10 nodes 
N0 – 8 nodes 
N1 – 9 nodes 
Not reported Not reported 
Tekkis et al.[40] 
(n= 8409) 
Not reported Not reported A – 9.4 nodes 
B – 11.6 nodes 
C1 – 11.8 nodes 
C2 – 14.3 nodes 
Not reported 
Mekenkamp et al. 
[38], (n=1530) 
Node negative 
T1 – 5.3 
T2 – 7.1 
T3 – 8.6 
T4 – 9.7 
Node positive 
T1 – 8.5 
T2 – 10.5 
T3 – 10.3 
T4 – 13.7 
Not reported Not reported Not reported 
Ha et al. [84] 
(n=615) 
Not reported Not reported Not reported I – 15.1 nodes 
II – 17.7 nodes 
III – 18.8 nodes 
Dilman et al. [48] 
(n=574) 
T1/2 – 15.3 nodes 
T3/4 – 19.5 nodes 
Not reported Not reported Not reported 
* The studies by Chou[82] and Baxter[89] are both retrospective analyses of SEER data with periods of 
study overlapping and therefore in part contain the same patients 
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In addition to pathological stage, tumour size has also been found to 
independently affect lymph node harvest.  Chou and colleagues, in the largest 
reported study of factors impacting on harvest, reported that for every 1cm 
increase in tumour size a 2-3% increased yield was observed [82].  Data from 
the Dutch rectal cancer radiotherapy found that harvests increased by 3 
nodes between tumours measuring <2cm and 2-5cm and by a further 3 nodes 
from 2-5cm and >5cm [38].  Rullier et al. in a smaller single centre study of 
factors impacting on harvest in rectal cancer specimens found that splitting 
specimens into those with a primary tumour less than 4cm in size and greater 
than 4cm conferred an increase in yield of 6 nodes (median 12 versus 18 
nodes respectively)[83].   
 
0.11  Tumour location 
Tumour location and type of surgical resection have both been found to 
influence nodal yield following resection.  The literature can be split into 
studies that have examined colonic cancers only, rectal cancers only and 
colon and rectal cancers in the same series.  Studies that have examined 
both colonic and rectal cancer in the same series have found the yield 
following rectal resection is lower than colonic resection.  Chou et al. [82] in 
the largest reported series found that colonic resections yielded a median of 
11 nodes per patient against 8 nodes following rectal resection.  Ostadi et 
al.[53] found that rectal cancers yielded 3 less nodes than colonic tumours.  
Baxter et al.[44] found that right sided colonic tumours yielded the highest 
harvest with 11 nodes per resection against a yield of 7 nodes for left sided 
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colonic and 8 nodes for rectal cancer.  The finding that right sided colonic 
resections have a higher yield than left sided is supported by other series [19, 
48, 82, 85] including those that have limited their study to just colonic 
tumours.  Analysis of New Zealand [19] and Dutch [85] cancer registry data, 
limited to patients with colonic disease, found that right sided resections yield 
2.7 and 2 more nodes per patient than left sided tumours respectively.  
Analysis of 8409 patients in the United Kingdom’s ACPGBI bowel cancer 
audit found that the highest yields were for sub/total colectomy and right 
hemicolectomy, with the lowest yield procedures being sigmoid colectomy 
(9.7 nodes), abdominoperineal excision of rectum (8.5 nodes) and Hartmann’s 
procedure (4.9 nodes)[40].  The reasons why right sided resections provide 
higher yields than left are poorly understood but could relate to longer 
specimens and increased volume of lymph node containing mesenteric tissue 
around the right hemicolon.  
 
Several series have specifically looked at lymph node harvest following rectal 
cancer resection [38, 83, 84, 90].  Two consistent findings are apparent in 
these studies; lymph node yield is lower after abdominoperineal excision of 
rectum (APER) than after anterior resection (AR) and use of pre-operative 
neoadjuvant therapy reduces nodal harvest.   Data from the Dutch 
radiotherapy in rectal cancer trial found that APER was associated with 2.7 
nodes less per patient than AR [38], Rullier et al. in a single centre 495 
patient, 10 year experience of treating rectal cancer found that following multi-
variate analysis APER conferred a 4.2 node less yield than AR [83].  The 
afore mentioned study from UK ACPGBI data reported that harvest following 
 44 
APER was 2.2 nodes less than after AR [40].  In the same study use of pre-
operative radiotherapy reduced nodal yield by two nodes per patient, similar 
numeric differences were observed in the Dutch rectal cancer radiotherapy 
[38]trial and in the reported by Rullier et al. [83]. 
 
0.12  Emergency presentation 
In general, patients presenting as an emergency with bowel cancer do so at a 
more advanced pathological stage than those operated on electively[91].  It 
may therefore be expected that patients undergoing emergency resection 
may have higher harvests than their counterparts having elective surgery, 
given that more advanced tumours have higher nodal yields. However, few 
studies have addressed whether surgical urgency impacts on nodal yield.  
Tekkis et al.[40] in the UK ACPGBI lymph node study found, using multi-
variate analysis, that emergent operations were associated with 0.8 nodes per 
resection less than elective procedures.  Ostadi et al. [53] in a small single 
centre series found on univariate analysis that emergency surgery harvested 
less nodes, although on multivariate analysis this difference was accounted 
for by other co-founding variables.  The only other study that investigated 
whether operative urgency plays a roll in harvest has found no difference 
between elective and emergent resections[49].  
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0.13  Laparoscopic surgery 
Another surgical factor that could potentially impact on lymph node retrieval is 
laparoscopic CRC resection[92].  The technique was first described in the 
1990’s [93] but has only recently been popularised in the UK, partly due 
concerns about the oncological adequacy of the technique compared to 
conventional open surgery[94, 95].  One oncological concern was that it would 
not be possible to perform as radical an excision of the mesentry and lymph 
node basin by laparoscopic compared to open surgery.  This was due to the 
perceived technical difficulty of dividing the main arterial pedicle as close to its 
origin as possible when a laparoscopic approach was used.  However, the 
results of the four principal RCTs comparing open against laparoscopic 
colorectal resection have used lymph node harvest as an outcome measure 
and found no difference in the harvests achieved (results are summarised in 
table 0-5) [96-99].  These results were recently subjected to meta-analysis 
which confirmed that their was no difference in the harvests achieved [100]. 
Table 0-5  Comparison of the lymph node harvests in the four principal 
RCTs comparing open and laparoscopic colorectal cancer resection   
 
Trial Name 
Open Lymph Node 
Harvest 
(n patients) 
Laparoscopic Lymph 
Node Harvest 
(n patients) 
 
p value 
Barcelona[101] Mean 11.1 
(n=108) 
Mean 11.1 
(n=111) 
p=ns 
CLASSIC[97] Median 12.5 
(n=268) 
Median 11 
(n=526) 
p=ns 
COLOR[96] Median 11 
(n=621) 
Median 11 
(n=627) 
p=0.35 
COST[99] Median 12 
(n=428) 
Median 12 
(n=435) 
p=ns 
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This literature review of factors that influence lymph node harvest has shown 
that factors relating to the surgeon, the pathologist, the tumour, the patient 
and use of neo-adjuvant treatment will all impact on the harvest of any one 
individual patient. One chapter of this thesis will study the factors that 
influence lymph node yield in two colorectal Multidisciplinary Teams (MDTs) 
linked by the re-location of a consultant colorectal surgeon mid-way through 
the study period.  
 
0.14  Harvest as a Marker of Quality in Bowel Cancer Management 
 
The Bristol enquiry into paediatric cardiac surgery mortality [102] resulted in 
increased scrutiny of surgical outcomes and comparative audit in the UK.  The 
report recommended that there, “must be agreed and published standards of 
clinical care for healthcare professionals to follow” and that, “there must also 
be a system of external surveillance to review patterns of performance over 
time”.   In the management of bowel cancer, both in the UK and the US, there 
has been interest in identifying outcome measures of bowel cancer treatment 
that are suitable markers of performance and quality to facilitate audit.  Lymph 
node harvest has been suggested as a suitable marker[103-107]. There is a 
sound rationale for its use in this way[108].  Lymph node status is one of the 
key determinants of a patient’s chance of cure and has significant impact on 
the use of adjuvant chemotherapy, therefore as a quality indicator harvest is of 
importance.  Additionally, lymph node harvest may be considered to reflect the 
quality of both surgeon and pathologist and therefore has cross-disciplinary 
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importance rather than reflecting the good or bad practice of one individual.  
Finally, a good quality indicator should be easily found in the patients’ medical 
record, since the publication of a minimum dataset for reporting colorectal 
cancer[109], nodal harvest has been found to be well reported in most 
units[110].  Harvest therefore has merit for use as a marker of quality, 
although it must be recognised that it is just one aspect of managing colorectal 
cancer and other measures also have merit and should not be forgotten[111].    
 
 
0.15  Impact of National Guidance on Lymph Node Harvest 
 
In the UK, guidance on lymph node harvesting following colorectal resection 
was issued by the National Institute of Clinical Excellence (NICE) in 2004 [26].  
The guidance stated, 
 
“In patients with colon cancer treated with curative intent, 12 or 
more nodes should normally be examined; if the median number 
is consistently below 12, the surgeon and the histopathologist 
should discuss their techniques” 
 
The professional bodies of the UK’s colorectal surgeons (ACPGBI) [27] and 
pathologists (Royal College of Pathologists) [28] have issued guidance 
identical to NICE viz 12 lymph nodes should be harvested following colorectal 
resection.  Similarly, the AJCC in the United States have issued a 12 node 
guidance [112].  On both sides of the Atlantic these guidelines have seen 
 48 
increases in nodal harvests in large population studies[44, 85].  In the year 
that the NICE guidance was introduced the ACPGBI bowel cancer reported 
that the UK median harvest was 10 nodes / patient and only 35% of patients 
undergoing resection had an harvest that exceeded 12 nodes[107].  One 
chapter in this thesis will examine the impact that national guidelines and audit 
have had on lymph node harvests since the NICE guidelines were 
published[26].   
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Thesis Aims 
 
The aims of this thesis are:  
 To perform risk adjusted comparative audit of lymph node harvesting in 
a single unit and of the surgeons and pathologists who staffed the unit. 
 
 To study factors that influence lymph node harvest following CRC 
resection, with particular regard to the impact of surgeon and 
pathologist performance. 
 
 To study the impact that working with a different MDT, following 
geographical relocation, has on a surgeon’s reported lymph node yield 
following colorectal resection. 
 
 To study the impact that guidelines for nodal harvest and comparative 
national audit against guidelines have on national performance. 
 
 To study what variables impact on five year survival following colorectal 
cancer resection  
 
 To study the impact that lymph node harvest has on survival following 
colorectal cancer resection. 
 
 To evaluate the use of lymph node ratio as a prognostic indicator in 
lymph node positive colorectal cancer 
 50 
 
 
Chapter 1 
 
Surgeon and Pathologist as variables on lymph node harvest 
following bowel cancer surgery
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Section A –  Unit comparative audit of lymph node harvest and factors 
Influencing lymph node yield 
 
1.1  Introduction 
 
Accurate staging of CRC relies on the identification of lymph node (LN) 
metastases.  Consequently, national guidance from NICE [26], the 
Association of Coloproctology of Great Britain and Ireland (ACPGBI) [27] and 
the Royal College of Pathologists (RCPath)[28],  have recommended that 
twelve nodes/patient are examined following colorectal cancer resection.  The 
RCPath and ACPGBI have also recommended annual audit of a units’ LN 
harvest.  
 
The ACPGBI annual audit and Welsh Bowel Cancer Audits (WBCA) have 
reported LN harvests, as part of their national audit programme, since 
2002[113].  However, one potential problem with comparative audit is that 
varying case mix between units, rather than differing performance may 
account for any observed differences.  Consequently, in 2004 the ACPGBI 
audit team carried out multilevel multifactorial regression analysis of the 
factors that may have impacted on LN yield to develop a multifactorial 
predictive model for lymph node harvest[107].  This model uses patient and 
operative variables to allow units to calculate their adjusted lymph node 
harvest against national data, which allows adjusted comparative audit to be 
performed.  The model is available on-line at www.riskprediction.org.uk. The 
ACPGBI LN model is shown in appendix 4. 
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1.2  Aims 
The aims of this section of chapter one were, to carry out in a single MDT: 
i.  Comparative audit including surgeon and pathologist performance of LN 
retrieval against the national guidance of 12 nodes / patient, with adjustment 
using the ACPGBI lymph node harvesting model[107]. 
ii.  An examination of factors that influence lymph node retrieval in surgery for 
colorectal cancer 
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1.3  Patients and Methods 
 
The study population was 436 patients undergoing resection for 
adenocarcinoma of the colon or rectum, operated on in a single unit (Princess 
of Wales Hospital (POWH), Bridgend), between April 1999 and April 2005.  All 
patients undergoing resectional surgery during the study period were 
identified form the prospectively collected ACPGBI database as part of the 
ACPGBI national audit.  Patient and tumour data was also retrieved from this 
database.  Individual pathology reports were retrieved from the hospital 
pathology database to validate the information recorded in the ACPGBI 
database and to identify the reporting pathologist.    
 
All resections were carried out under the care of one of four colorectal 
surgeons (one of whom was appointed in the final year of the study) or one of 
four general surgeons with other sub-specialty interests, who staffed the unit 
during the study period.  All cases were performed by an open technique. 
 
All pathology specimens were reported by one of three resident Consultant 
Pathologists, or one of several locum Consultant Pathologists, who staffed the 
unit during the study period.  The specimens were examined by a standard 
technique, which sliced the colon and mesentery at right angles to the axis of 
the bowel at 10mm intervals and any nodes on the upper surface were 
removed and sampled. The specimen was then sectioned at 5mm intervals 
parallel to the colonic axis (perpendicular to the first slicing) and any further 
nodes identified were removed and examined.  
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1.4  Unit comparative audit of risk adjusted nodal harvest 
Data for all patients was entered into the ACPGBI LN harvesting model[107] 
(www.riskprediction.org.uk) to calculate individual predicted lymph node 
harvest (LNH), see appendix 5.  Observed and predicted nodal harvest 
underwent logarithmic transformation to obtain the geometric mean of 
observed and predicted nodal harvests. 
 
Adjusted nodal counts for each year of the study were calculated using the 
following formula: 
     
Adjusted nodal count =    
  
log 10 observed LNH      x    log 10national median LNH 
                   log 10 predicted LNH 
 
 
Median LN harvests across Wales were obtained form the annual national 
bowel cancer reports[39, 114, 115] to calculate adjusted nodal count. 
 
 
1.5  The effect of Surgeon and Pathologist on lymph node retrieval 
Unit, surgeon and pathologist raw (observed) and adjusted (ACPGBI model) 
lymph node harvests were compared.  Case mix for each individual surgeon 
and pathologist was also compared.  
 
1.6  Factors influencing lymph node retrieval  
The patient and operative factors collected are shown in table 2 and were 
studied by uni and multivariate analysis.  Patients who received pre-operative 
 55 
neoadjuvant therapy were excluded from analyses of pathological variables 
due to the uncertainty of the final pathological stages following this therapy.  
Sub-group analysis of patients undergoing rectal resection was also 
undertaken to examine any affect that the use of pre-operative neo-adjuvant 
therapy may have had on LN yield.  Comparison between patients with 
inadequate and adequate lymph node harvests (< 12 and ≥12 nodes/ patient, 
NICE/AJCC guidance) was also undertaken. 
  
1.7  Effect of node retrieval on the identification of lymph node 
metastases 
Patients who had at least one lymph node metastasis underwent sub-group 
analysis to look for a relationship between the number of nodes examined and 
the likelihood of detecting a metastasis.   
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1.8  Statistical Analysis 
 
The normality of distribution of the lymph node harvest data was tested with 
the Kolmogrov-Smirnov test, which demonstrated that the data was not 
normally distributed.  Lymph Node Harvest for comparative audit against 
national performance therefore underwent logarithmic adjustment prior to 
comparison, as described in the methods section.  Unadjusted differences in 
the mean number of lymph nodes harvested during surgery (with 
corresponding 95% confidence intervals) were calculated according to the 
consultant surgeon and reporting pathologist and statistical significance 
between individuals compared using the Kruskal-Wallis H test.  Case mix 
between individual surgeons and pathologists was examined using a Chi-
squared test.  Uni-variate analysis of factors that influenced lymph node 
retrieval was carried out using Pearson’s correlation, Mann-Whitney U test or 
the Kruskal–Wallis H test. Significance was assumed for all tests at the 5% 
level.  Independent effects of variables that were significant in univariate 
analysis were assessed using multiple regression analysis.  The effect of 
lymph node harvest on identification of LN metastases was assessed with 
Pearson’s correlation and Mann Whitney U test.  The data were analysed 
using SPSS  versions 11.0 & 16.0 for Mac statistical software (SPSS 
Chicago, Illinois, USA). 
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1.9  Results 
 
During the study period 436 patients had surgical resection of their bowel 
cancer in the unit.  The unit overall median lymph node harvest was 13 
nodes/patient (Range 0-42, IQR 9-18, Mean 13.69 95% C.I. 13.03-14.69). 
 
1.10  Unit Comparative Audit 
The unadjusted raw results of lymph node harvest are presented in table 1-1. 
 
Table 1-1 Unadjusted lymph node harvest by year of study 
 
Year of Study 
 
Number of cases 
 
Median Harvest 
 
IQR 
 
Range 
1999-2000 65 14  10-19 3-31 
2000-2001 65 14  9-20 1-42 
2001-2002 62 12 8-17 2-30 
2002-2003 67 12 8-16 1-32 
2003-2004 77 13 8-18 0-30 
2004-2005 100 13 9-18 1-40 
 
 
The Kolmogrov-Smirnov test demonstrated that the lymph node harvest data 
was not normally distributed (KS= 0.081, df 436, p<0.0001).  To carry out unit 
comparative audit the data therefore underwent logarithmic transformation.  
The results of risk adjustment are presented in table 1-2. 
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Table 1-2 Risk adjusted lymph node harvest 
Year of 
Study 
Median Log 
Transformed 
Observed 
Harvest 
Median Log 
Transformed 
Predicted 
Harvest 
National 
Median 
Harvest 
Risk Adjusted 
Median 
Harvest 
1999-2002 13.49 9.55 9[39]* 12.59* 
2002-2003 12.02 9.33 7[39] 8.70 
2003-2004 12.88 9.12 9[114] 12.68 
2004-2005 12.59 9.12 8[114] 10.715 
 
* national audit of lymph node harvest was first reported in 2001-2002, the figures from this 
year have been used to risk adjust unit performance between 1999-2002 
 
Unit risk adjustment of results demonstrated that unit performance was above 
nationally reported results.  The low value of the adjusted median harvest in 
the year 2002-3 can be explained by the low national yield of seven 
nodes/patient observed in that year of study.  
 
1.11  The effect of Surgeon and Pathologist on lymph node retrieval 
The case mix of operation type for individual surgeons and pathologists is 
given in Table 1-3.  There was no difference in lymph node retrieval between 
surgeons within the unit, colorectal specialists and general surgeons with 
other sub-specialist interests retrieved similar numbers of lymph nodes 
(Kruskal – Wallis, p=0.071, Table 1-4).  However, examination of case mix 
demonstrated that non-colorectal specialists carried out proportionately more 
right sided resections (X2 =10.087, p= 0.001), when a greater number of 
nodes would be expected.  There was no statistical difference between the 
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numbers of left sided or rectal resections.   There was however, a significant 
difference in lymph node retrieval between pathologists (Kruskal-Wallis 
p<0.001, Table 1-4). There was no difference in case mix amongst 
pathologists (table 1.  Mean lymph node harvests and 95% confidence 
intervals for surgeon and reporting pathologist are shown in figure 1-1 and 1-
2.  Predicted harvests (ACPGBI model) for most individual surgeons were 
similar (between 9.3 and 9.6) with the exception of the lowest volume (newly 
appointed colorectal surgeon) who had a lower predicted harvest (equal to 8.0 
nodes per patient).  Pathologist predicted harvests were between 9.0 and 
10.3 nodes per patient.  
 
Table 1-3 Case mix for individual surgeon and pathologist 
 
 Surgeon 
 
 1 
 
(n=183) 
2 
 
(n=104) 
3 
 
(n=86) 
4 
 
(n=15) 
Non 
CRC 
(n=48) 
Sub-total 
 
3% 10% 11% 0 2% 
Right Colon* 
 
34% 34% 31% 20% 56% 
Left/Sigmoid** 
 
29% 23% 15% 20% 18% 
Rectum 
 
33% 34% 43% 60% 23% 
  
Pathologist 
 
 1 
 
(n=215) 
2 
 
(n=122) 
3 
 
(n=81) 
Locum 
 
(n=18) 
Sub-total 
 
6% 6% 6% 11% 
Right Colon* 
 
38% 36% 32% 22% 
Left/Sigmoid** 
 
23% 25% 24% 22% 
Rectum 
 
34% 34% 38% 44% 
 
*Right Colon includes Right Hemicolectomy, Extended Right Hemicolectomy and Transverse Colectomy 
** Left Colon/sigmoid includes Left Hemicolectomy, Sigmoid Colectomy and Hartmann’s for non-rectal 
cancer  
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Table 1-4 Lymph node harvest by individual surgeon and pathologist 
 Surgeon 
 
 1 
 
(n=183) 
2 
 
(n=104) 
3 
 
(n=86) 
4 
 
(n=15) 
Non 
CRC 
(n=48) 
Median LN 
harvest 
(range) 
12 
(1-37) 
14 
(1-42) 
14 
(0-30) 
9 
(2-20) 
14 
(1-33) 
Median 
Predicted 
Harvest 
9.3 9.6 9.3 8.0 9.4 
log-rank p=0.071  
 
  
Pathologist 
 
 1 
 
(n=215) 
2 
 
(n=122) 
3 
 
(n=81) 
Locum 
 
(n=18) 
Median LN 
harvest 
(range) 
14 
(2-42) 
13 
(1-40) 
10 
(0-29) 
11 
(1-39) 
Median 
Predicted 
Harvest 
9.4 9.4 9.0 10.3 
log-rank p<0.001 
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Figure 1-1-  Individual surgeon mean LN harvest and 95% confidence 
intervals 
 
 
Top horizontal line equals NICE / ACPGBI / RCPath recommended 
minimum of 12 nodes.  Bottom horizontal line is the ACPGBI model 
predicted harvest for the unit.   
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Figure1-2 Reporting pathologist mean LN harvest and 95% confidence 
intervals 
  
 
Top horizontal line equals NICE / ACPGBI / RCPath recommended 
minimum of 12 nodes.  Bottom horizontal line is the ACPGBI model 
predicted harvest for the unit.   
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1.12  Factors influencing lymph node harvest in colorectal cancer 
 
Factors found to be significant determinants of LN harvest on univariate 
analysis were operation type, Dukes’ stage, T stage and N stage of the 
tumour, reporting pathologist and the use of pre-operative radiotherapy in the 
treatment of rectal cancer (Table 1-5). In addition to the results in the table, 
the impact of age on lymph node yield was examined with Pearson’s 
correlation, which demonstrated that age did not have an impact on nodal 
yields (Pearson’s r= -0.039, p=0.442) in this study.   
 
The factors that were significant on univariate analysis were entered into a 
multivariate backward linear regression model.  In this model, with analysis of 
all patients operated on without pre-operative neo-adjuvant therapy (colon 
and rectal cancers), the following were found to independently predicted 
harvest:  reporting pathologist (p=0.001), T-stage (p<0.001), N stage 
(p=0.011) and operative type (p<0.001).  Multivariate backward linear analysis 
of patients undergoing resection for rectal cancer (including patients treated 
with pre-operative neoadjuvant therapy) demonstrated that use of pre-
operative radiotherapy was not an independent predictor of reduced nodal 
harvest but T stage (p<0.001), N stage (p=0.001) and reporting pathologist 
(p=0,014) were. 
 
 
 
 64 
Table 1-5 - Univariate analysis of factors influencing LN yield 
 
Variable 
Number Median LN 
Harvest 
p value 
ASA* I 
II 
III 
IV 
V 
82 
200 
127 
21 
3 
12 
13 
13 
12 
12 
 
 
p = NS 
Operation type Right/ Extended Right 
Hemicolectomy 
Transverse Colectomy 
Left Hemicolectomy 
Sub-total Colectomy 
Sigmoid Colectomy 
Hartmann’s Procedure 
Anterior Resection 
APER 
 
150 
5 
22 
26 
37 
56 
102 
38 
 
15 
14 
13 
20 
11 
12 
10 
11 
 
 
 
 
 
p<0.001 
Operative urgency Elective 
Urgent 
Emergency 
377 
51 
8 
13 
14 
20 
 
p= NS 
Surgical intent Curative 
Palliative 
349 
87 
14 
13 
 
p = NS 
Operating 
Surgeon 
Colorectal 1 
Colorectal 2 
Colorectal 3 
Colorectal 4 
Non CR 
183 
104 
86 
15 
48 
12 
14 
14 
9 
14 
 
 
p = NS 
Dukes’ stage** 
(pre-operative 
radiotherapy 
cases excluded) 
A 
B 
C 
D 
41 
166 
175 
10 
9 
13 
15 
13 
 
 
p<0.001 
T stage 
(pre-operative 
radiotherapy 
cases excluded) 
1 
2 
3 
4 
18 
40 
218 
116 
9 
11 
14 
15 
 
 
p<0.001 
N stage 
(pre-operative 
radiotherapy 
cases excluded) 
0 
1 
2 
205 
100 
87 
12 
14 
16 
 
 
p<0.001 
Reporting 
Pathologist 
1 
2 
3 
Locum 
215 
122 
81 
18 
14 
13 
10 
11 
 
 
p<0.001 
Year of study 1999-2000 
2000-2001 
2001-2002 
2002-2003 
2003-2004 
2004-2005 
65 
65 
62 
67 
77 
100 
14 
14 
12 
12 
13 
13 
 
 
 
p= NS 
Use of pre-
operative 
radiotherapy in 
rectal cancer 
Anterior Resection with*** 
Anterior Resection without*** 
APER with 
APER without 
Hartmann’s with*** 
Hartmann’s without*** 
22 
58 
18 
20 
4 
32 
8 
11 
5 
12 
10 
11 
 
 
p=0.003 
*    ASA data missing on 3 patients 
**  Dukes’ stage clinicopathological 
***Anterior resections & Hartmann’s procedures carried out for non-rectal cancer excluded 
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1.13  Effect of node retrieval on the identification of lymph node 
metastases 
 
A total of 184 patients (47.1% of cases treated without pre-operative 
neoadjuvant therapy) had one or more positive lymph nodes identified.  This 
group had greater median nodal harvest than those with negative nodes 
(median 15 versus12 respectively, Mann-Whitney U= 15535, p=0.002). 
Differentiating the cohort into groups of patients who had 12 or more nodes 
assessed demonstrated that 39.2% of patients were staged as node positive 
(N1 or N2) following assessment of ≤ 12 nodes against 53.5% who were had 
> 12 nodes assessed, (x2 = 7.926, p=0.005).  Correlation between LN harvest 
and incidence of LN positivity confirmed that patients with higher harvests 
were more likely to have nodal metastases compared with patients with lesser 
harvests (Pearson Correlation r=0.141, p=0.005).  
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1.14  Summary of the Principal Findings in Section A 
 
1.  Lymph node harvests following CRC resection in this unit have been 
shown to exceed that of national standards using risk adjusted comparative 
audit against national data. 
2.  There was no statistical difference in lymph node harvest between the 
eight surgeons who staffed the unit during the study period.  Case mix 
between surgeons was broadly similar, however non-specialist General 
surgeons did perform significantly more right sided resection than their 
colorectal sub-specialist colleagues.  
3.  There was a significant difference in LN harvest amongst the three 
pathologists within the unit.  The reporting pathologist was found to be an 
independent predictor of LN harvest.  All pathologists had a similar case mix.  
One pathologist had a mean harvest below the 12 node guidance and this 
individual’s harvest was significantly lower than that of other pathologists in 
the unit. 
4.  Uni-variate analysis of patient and pathological variables that may have 
impacted on LN harvest demonstrated that operation type (higher yield with 
more proximal tumour), higher Dukes’ stage, higher T stage, higher N stage 
and no use of pre-operative radiotherapy were associated with greater lymph 
node yields.  On multi-variate analysis, in addition to reporting pathologist, 
operation type and increasing T and N stages were associated increased 
yields. 
5.  Patients with higher LN yields were more likely to have LN metastases 
identified. 
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Section B -  The Pathologist as a variable on lymph node harvest – an  
inter hospital study 
 
1.15  Introduction 
LN retrieval is dependent on variables that relate to patient characteristics, the 
operation and the techniques of both the operating surgeon and reporting 
pathologist.  Previous studies have shown inter-unit variability in lymph node 
harvests following surgical resection of bowel cancer[40, 44, 46].  It is not 
clear however, whether inter-unit variability is due to variations in patient 
characteristics, surgical technique or pathological technique.    
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1.16  Aim of Section B 
The aim of this section of chapter one was to compare the LN harvests in 
patients undergoing CRC resection by a single surgeon, working in different 
MDTs, in two separate units, following geographical relocation, thereby 
standardising surgical technique. 
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1.17  Patients and Methods 
 
The study population consisted of 213 patients undergoing consecutive 
potentially curative CRC resection for adenocarcinoma, operated on by a 
single Consultant Surgeon, in two units, over a seven year period. The 
surgeon moved from the Princess of Wales Hospital (POWH), Bridgend (unit 
1) to Heartlands Hospital, Birmingham (unit 2) in July 2005.  In unit one 110 
cases were operated on between October 2002 to July 2005, and 103 cases 
in unit two, between August 2005 to October 2009.  Patients were identified 
from prospectively collected databases at the two centres.  Individual 
pathology reports were retrieved from the hospital pathology database and 
reviewed.  All cases were carried out by an open technique and there was no 
change in surgical technique during the study period.  All cases were either 
performed by the Consultant Surgeon or by a trainee under direct supervision 
of the surgeon. CRC screening was introduced into the second unit during the 
study period and eight cases performed in this unit were screen detected.  
 
Pathological reporting of the resected specimens was performed by one of 
eleven Consultant Pathologists at the two units (three at unit one and eight at 
unit two).  At the second unit, five pathologists had reported more than five 
specimens and the remaining three pathologists had reported less than five 
cases each.  The results of the three pathologists reporting less than five 
cases were therefore pooled, totalling eight cases for analysis in this study.   
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Both units had broadly similar pathological laboratory standard operating 
policies for the retrieval of LNs from CRC specimens which consisted of:  
fixation in formalin, cutting through the mesenteric tissue in slices parallel to 
the bowel wall, followed by careful manual dissection of all LNs out of the 
specimen.  Neither unit used fat clearing techniques.   
 
Data recorded for each patient and compared between units included overall 
LN harvest and case mix assessed by comparison of patient age, site of 
operation (divided into right colon, left colon and rectum), operative urgency 
(elective or emergency), T stage (rectal cases treated with pre-operative 
radiotherapy were excluded in analysis of this variable) and the use of 
neoadjuvant radiotherapy in rectal cancer. 
 
Factors that may have influenced LN harvest in addition to unit of operation 
(shown in table 1-8) were examined with univariate analysis.  Significant 
factors on univariate examination were then assessed with multivariate 
analysis.  Lymph node harvests, according to tumour location in right colon, 
left colon and rectum, were recorded and compared between units. 
 
The proportion of LN positive (Dukes’ C) cases were compared between units 
and the LN harvest of LN positive and LN negative cases compared within the 
individual units.  The effect overall LN harvest had on rates of LN positive 
cases across the whole series was also examined. 
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1.18  Statistical analysis 
 
Median values were used to compare all variables.  Overall LN harvest 
between centres was compared using the Mann Whitney U-test.  Case mix 
between the units was compared with Mann Whitney U-test and Chi-squared 
test, as appropriate.  
 
Factors influencing LN retrieval were examined with Pearson’s Correlation 
Coefficient, Mann Whitney U-test and Kruskal Wallis H-test as appropriate.  
The independent effect of variables that were significant on univariate 
analysis were assessed using multiple backward regression analysis.  
Significance was assumed for all tests at the 5% level.  The data were 
analysed using SPSS® versions 11.0 and 16.0 for Mac statistical software 
(SPSS, Chicago, Illinois, USA). 
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1.19  Results 
 
There were 110 cases carried out in unit one and 103 cases in unit two.  
Overall median LN harvest was significantly different between units, unit one 
13 nodes/patient (range 0-30, 95% C.I 11.7-14.0) and in unit two 22 
nodes/patient (range 4-102, 95% C.I 23.0-29.6), p<0.001 (see figure 1-3).   
 
 
Figure 1-3: Boxplot of Lymph Node Harvest at the Two Units 
 
 
 
 
 
Figure 1-3 – Boxplots of LN harvest at the two units.  Grey boxes represent 
the interquartile range, black horizontal line within the grey box the median LN 
harvest, the whiskers represent the range with circles representing statistical 
outliers. 
 
Mann Whitney 
p<0.001 
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Comparison of case mix, patient age, operative urgency and tumour T stage 
is presented in table 1-6.  Case mix according to tumour site was similar 
between units.  
 
Table 1-6 Case mix between units      
  Unit 1 Unit 2 
  Percentage of 
total cases 
Percentage of 
total cases 
 
X2  
p value  
Right colon* 35% 
(38/110) 
40% 
(41/103) 
p=0.427 
Left colon** 20% 
(22/110) 
25% 
(26/103) 
p=0.360 
Rectum 45% 
(49/110) 
35% 
(36/103) 
p=0.153 
 
 
Tumour 
location 
Panproctocolectomy 1% 
(1/110) 
0% NA 
 
Median patient age 
 
 
72 
 
71 
 
p=0.789 
 
Operative 
urgency 
 
 
Elective 
 
Emergency 
 
86% 
(95/110) 
14% 
(15/110) 
 
 
90% 
(94/103) 
10% 
(10/103) 
 
 
p=0.373 
 
 
T stage*** 
 
 
 
1&2 
 
3&4 
 
21% 
(19/89) 
79% 
(71/89) 
 
20% 
(17/84) 
79% 
(67/84) 
 
 
p=0.857 
 
* Right colon includes right hemicolectomy, extended right hemicolectomy, sub-total 
colectomy and transverse colectomy 
** Left colon includes left hemicolectomy, sigmoid colectomy and Hartmann’s procedure for 
colonic tumours and high anterior resection for colonic/rectosigmoid tumours 
*** Rectums with pre-operative radiotherapy excluded 
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1.20  Comparison of LN yield according to colonic or rectal tumour 
location 
Analysis of LN harvest according to whether the tumour was colonic (right and 
left combined) or rectal, demonstrated that colonic (unit one median 15 nodes 
vs. unit 2 median 18 nodes, p=0.014) and rectal (unit one median 10 nodes vs 
unit two median 31 nodes, p<0.001) were higher in the second unit. Analysis 
of LN harvest according to tumour location demonstrated that LN harvests 
were significantly higher in left colonic and rectal tumours in the second unit, 
but identical in tumours of the right colon (table 1-7).  Intra unit analysis 
demonstrated unit one had higher LN harvests in colonic cases (colon median 
15 nodes. vs. rectum median 10 nodes, p<0.001) whereas in unit two, higher 
LN harvests were observed in rectal cases (colon median 18 nodes vs. 
rectum 31 nodes, p=<0.001).     
Table 1-7 : Lymph node harvest according to tumour location between 
units 
 
 Unit 1  Unit 2 
 Median LN 
harvest/patient 
(range) 
Median LN 
harvest/patient 
(range) 
 
p 
value 
Right colon 16 (5-26) 17 (5-47) 0.253 
Left Colon 15 (6-30) 21 (4-64) 0.023 
Rectum (overall) 10 (0-22) 
 
31 (5-102) <0.001 
 Rectum without preop 
radiotherapy 
11 (0-22) 
n=29 
25 (21-102) 
n = 17 
<0.001 
 Rectum with pre-operative 
radiotherapy 
7 (1-20) 
n=21 
41 (20-70) 
n=19 
<0.001 
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1.21  Factors influencing LN retrieval 
Speculative univariate analysis of the factors that may have influenced overall 
LN harvest, at the two centres demonstrated that, in addition to the unit, 
significant variables for LN retrieval were: T stage and reporting pathologist 
(table 1-8).  Age was not found to be a significant variable (Pearson’s co-
efficient r= -0.048, p=0.487) Backward linear regression analysis showed that 
unit (p<0.001) and reporting pathologist (p=0.007) were the only 
independently significant variables.   
 
1.22  Proportion of cases that were Dukes’ C according to unit  
In unit one 46/110(42%) cases were LN positive and 49/103 (48%) in unit two, 
x2 p=0.398.  In unit one, the median LN harvest of patients who were LN 
negative was 11 nodes/patient and in those who were LN positive was 15 
nodes/patient, p=0.004.  In unit two the median LN harvest of node negative 
patients was 21 nodes/patient and, in those who were node positive, LN 
harvest was 23 nodes/patient, p=0.616. 
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Table 1-8: Analysis of factors that may have influenced overall LN 
retrieval 
 
Variable 
Number Median 
LN 
Harvest 
p value 
Unit 
 
Unit 1 
Unit 2 
110 
103 
13 
22 
P<0.001* 
Operation type Right Colon 
Left Colon 
Rectal 
 
Rectal with radiotherapy 
Rectal without radiotherapy 
80 
48 
85 
 
40 
45 
16 
17 
16 
 
16 
19 
p=0.761** 
 
 
 
 
p=0.996* 
Operative urgency Elective 
Emergency 
188 
25 
16 
15 
p=0.299* 
Final Dukes’ 
stage 
A 
B 
C 
45 
72 
96 
12 
16 
17 
 
p=0.158** 
T stage Complete response 
1 
2 
3 
4 
7 
14 
40 
114 
38 
7 
9 
18 
16 
17 
 
p=0.001** 
Reporting 
Pathologist 
Unit 1 
 
 
Unit 2 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 *** 
31 
39 
40 
37 
32 
12 
8 
6 
8 
15 
14 
11 
33 
15 
19 
23 
25 
24 
 
 
 
p<0.001** 
Clinical 
presentation 
Symptomatic 
Screen detected (all unit 2) 
205 
8 
16 
19 
p=0.195 
 
* Mann Whitney U test, **Kruskal- Wallis H test 
*** pooled results of 4 pathologists each reporting less than 5 cases 
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1.23  Effect of LN harvest on identification of LN metastases 
The effect of LN harvest on the identification of LN metastases is presented in 
figure 1-4.  Increased frequency of finding at least one metastatic node 
(Dukes’ C) was seen up to a harvest level of 36 nodes/patient. 
 
 
Figure 1-4: Lymph Node Harvest and Percentage of Cases Lymph Node 
Positive 
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1.24  Summary of the Principal Findings of Section B 
 
1.  A single surgeon who moved his place of work experienced significantly 
different reported lymph node harvest following CRC resection, with no 
change in surgical technique and similar case mix at the two units.   The 
implication of this finding is that the difference in LN retrieval relates to the 
pathological technique as the surgical technique was standardised. 
 
2.  It has previously been reported that LN harvests are generally lower after 
rectal than colonic resections.  In unit 1 proportionally more rectal resections 
were performed which it could be anticipated may have contributed to the 
lower overall harvest at unit 1.  However, in unit 2, rectal cancer specimens 
had significantly higher LN yield than colonic tumours.   
 
3.  Higher LN yields at the second unit were associated with a higher 
proportion of cases being staged a LN positive, although this difference was 
not statistically significant. 
 
4.  Patients with higher LN yields were more likely to have LN metastases 
identified. 
 
5.  On multi-variate analysis unit of operation and reporting pathologist were 
the only independently predictive factors influencing lymph node harvest. 
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1.25  Discussion Chapter 1, Sections A and B  
 
Section A of this chapter has studied lymph node harvest at a single unit 
(Princess of Wales Hospital (POWH), Bridgend).  Risk adjusted comparative 
audit of unit and individual surgeon and pathologist performance was 
performed and analysis of factors that influenced nodal harvest following 
bowel cancer resection was undertaken.  Section B studied the impact that 
relocating a surgeon from POWH to a new hospital (Heartlands Hospital (HH), 
Birmingham) had on nodal harvest for that surgeon (section B).   
 
The common finding from both these sections was that reporting pathologist 
was an independent predictor of nodal harvest following CRC resection.  The 
results of Section B are particularly pertinent, as they focus on the results of a 
single surgeon operating at two units with similar case mix, thereby 
standardising the surgical technique. The implication of this finding is that the 
difference in LN retrieval between units relates to the pathological techniques.  
The finding that a surgeon working at two centres can have differing harvest 
at each centre has only previously been reported once[42], however, in this 
series multivariate statistical analysis was not used as was used in the 
present study.   
 
A potential explanation for the observed difference in LN harvest between 
POWH and HH in section B is the separate chronological time periods that the 
harvests cover, i.e. POWH, years 2002-5 and HH, years 2005-9.  During the 
latter period, national nodal harvests across the UK have improved[103, 105, 
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116].  However, the results in section A showed that the median harvest at 
POWH between 1999-2005 was 13 nodes/ patient.  Re-audit of harvests at 
POWH for the period 2006-2007 showed that the median harvest was 
identical, at 13 nodes/patient[117]. Audit data on lymph node harvest in HH is 
unavailable for the time period when the surgeon was located in POWH.  
However, the unchanged harvest at unit one during both time periods 
suggests that the national trend of increasing LN yields has not impacted 
significantly on the individual surgeons’ results reported in this chapter.  
 
The median nodal harvest of 13 nodes / patient at POWH reported for the 
period 1999-2005 (section A) are higher than observed elsewhere in Wales 
over similar time periods[39, 114].  In section A, use of the ACPGBI lymph 
node model[107] to perform risk adjusted comparative audit has shown that 
the higher harvest in POWH are as a result of better performance at the unit, 
compared with other units in Wales, rather than the alternative explanation of 
a more favourable case mix.  It is noteworthy that the risk adjusted harvests of 
POWH appear very low, this is due to the low national harvests in this time 
period.  The ACPGBI model[107] was calibrated using data national lymph 
node harvest data up to 2004, the results in this chapter together with the 
national increase in harvests [103, 105, 116, 118] suggest that this model 
under predicts harvest and should be revised in light of changing clinical 
practice. 
 
It has previously been reported that lymph node harvests can be significantly 
increased by fat clearance techniques[55-57, 59].  Neither unit studied in this 
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chapter used fat clearance techniques.  A review of laboratory standard 
operating policies at both units showed there was no discernable difference in 
methods of specimen fixation or dissection.  This suggests that the intra unit 
differences in harvest between pathologists in section A and the inter unit 
differences in section B are attributable to the techniques of the individual 
pathologist rather than those of individual hospital laboratories. 
 
Lymph node harvests have been reported to be lower after rectal than colonic 
resection [53, 82]. the results in section A of this chapter support this finding.  
This difference between rectal and colonic lymph node yields could explain 
some of the lower LN harvest observed at POWH in section B, where 
proportionally more rectal resections were performed.  However, in HH, rectal 
cancer specimens had significantly higher LN yields than colonic tumours.  In 
addition, use of pre-operative radiotherapy for rectal cancer treatment has 
been widely reported to reduce nodal harvests [38, 40, 89, 119] and was 
observed to do so at POWH in section A of this chapter.  However, results 
from HH (in section B) show that radiotherapy use did not impact on nodal 
retrieval at this unit.  The likely explanation, for these apparent divergences 
from the norm, is that a pathologist with a particular interest in rectal cancer 
specimens reported most of the rectal cases at HH.  This pathologist has a 
declared specialist interest in rectal cancer reporting and has recorded some 
of the highest lymph node harvests for rectal cancer specimen reporting in the 
literature[120]. 
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Lymph node (LN) harvests are being suggested as surrogate markers of 
surgical quality in the treatment of bowel cancer [8, 111].  The results in this 
chapter highlight the potential strengths and weaknesses of this.  The results 
have shown that nodal harvest is not just dependent on the technical skill of 
the surgeon but is also strongly dependent on the pathologist, which as a 
quality marker in bowel cancer care has the advantage that it measures the 
performance of more than one individual within an MDT.  However, if the 
focus is on “surgical” quality, an underperforming pathologist could unfairly 
cause a surgeon to be labelled as underperforming, without reasonable 
foundation.  The results of colorectal surgeon four in section A emphasize 
another problem with using harvest as a quality indicator.  This individual had 
a lower harvest than their other colorectal specialist colleagues, although the 
difference was not statistically significant.  However, this surgeon was newly 
appointed and only carried out 15 resections in the study period, of which a 
far higher proportion were rectal resections that conferred a lower yield in 
POWH.  This highlights the importance and potential danger of comparing 
results of simple numbers without risk adjustment that allows for case mix.  In 
the case of colorectal surgeon four, risk adjustment identified that their 
expected harvest should be lower than their counterparts. 
 
In this chapter use of multi-variate analyses of the factors that predicted lymph 
node harvest found that in addition to reporting pathologist in section A 
operation type, T and N-stage predicted harvest and the unit of operation was 
the only other independent predictor of harvest in section B.  These factors 
have all previously been found to influence nodal harvest as discussed in the 
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introduction section of this thesis.  The reasons why more pathologically 
advanced tumours and proximal site of tumour predicted higher harvests in 
section A but not in section B are not clear.  It is possible that this represents 
a type II error, as the number of patients analysed in section B is smaller.  It 
may also relate to the influence of the pathologist with a special interest in 
rectal cancer specimen reporting in HH, whose high harvests following rectal 
cancer resection may have skewed the results of harvest and tumour site in 
section B.  This individual’s personal series has found that in his hands more 
pathologically advanced tumours do not confer an increased yield, as is 
commonly reported in the literature [38, 40, 48, 53, 82-84], but are associated 
with larger lymph nodes [120].    
 
The finding in both sections of this chapter, that patients with higher nodal 
harvests were more likely to have nodal metastases, is supported in previous 
studies [9, 121, 122].   Routine histological examination of nodes usually 
consists of a single slice through the identified node. This process examines 
less than one percent of the nodal tissue in a 5mm lymph node [123].  
Previous authors have looked at the technique of ultra-sectioning nodes and 
have found that this significantly increases the identification of nodal 
metastases [124, 125].  The finding in section B of this chapter that increased 
nodal yield at HH was associated with a trend towards a higher proportion of 
cases being staged as Dukes’ C further supports the potential benefit of 
optimising a patient’s harvest.  Although this difference was not statistically 
significant it is possible that this represents a type II statistical error and that a 
larger data set may yield a statistically significant result.  Although 
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recommendations are that a minimum of 12 nodes per patient be examined, it 
is probably appropriate that as many nodes as possible be examined [54], 
supported by an increase of nodal metastasis identification up to 36 nodes in 
this chapter.   
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1.26  Conclusions Chapter 1 
 
The results of risk adjusted comparative audit of lymph harvest against 
national data in this chapter suggest that the ACPGBI lymph node model 
under-predicts lymph node harvest and may need revision in light of changing 
clinical practice and improved national results.  The results presented also 
suggest that as many nodes as possible should be examined after colorectal 
cancer resection to minimise the risk of under staging a patient’s disease.  
This chapter has also confirmed reporting pathologist to be a critical 
determinant on the number of lymph nodes harvested following colorectal 
cancer resection.  This has implications for the use of lymph node harvest as 
a marker of “surgical” quality. 
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Chapter 2 
 
Impact of national audit against national guidelines on lymph 
node retrieval following colorectal cancer resection 
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2.1  Introduction 
 
The ACPGBI bowel cancer audit project evolved from large population audits 
in Wessex [126], Trent and Wales [127] and Scotland [128].  Lead clinicians 
from these audits developed a minimum dataset that started national audit of 
patients with bowel cancer in 2000. In 2003 the ACPGBI audit became 
known as the National Bowel Cancer Audit Programme (NBOCAP).  The 
ACPGBI and NBOCAP audits have produced annual reports since 2002.  
The early reports focused on producing a risk adjusted mortality model to 
allow comparative audit of mortality rates following surgery between units 
[104]. Subsequent reports have focused on other outcome measures, 
including lymph node harvest.  Data on Welsh patients has contributed to the 
national audits.  In addition, the colorectal steering group, part of the Cancer 
Services Co-ordinating Group (CSCG) in Wales has published separate audit 
reports including just Welsh patients.   
 
In 2004 NICE identified lymph node yield as a quality control indicator in 
colorectal cancer surgery [26].  It recommended that if a units’ median harvest 
was consistently below 12 nodes per patient, “the surgeon and pathologist 
should discuss their techniques”.  In 2005, the colorectal CSCG for Wales, 
following this NICE guidance, agreed lymph node harvest against this 
guidance would be one of its quality indicators that would be reported in 
subsequent annual Welsh Bowel Cancer Audit reports. 
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Prior to the NICE guidance in 2004 observed lymph node harvests in the 
ACPGBI NBOCAP national audits had consistently been below the 
recommended level of 12 (see table 2.1).  The situation in Wales over the 
same time period was reported in a separate Welsh Bowel Cancer Audit 
(WBCA) reports [39, 114].  At this time the WBCA reports documented that 
Welsh node harvests were lower than those observed UK wide (table 2.1)     
 
Table 2.1 – National and Welsh Lymph (CSCG) Node Harvest prior to 
implementation of NICE / CSCG Guidance  
UK ACPGBI / NBOCAP National Reports 
 
National Report 
 
Period covered by 
report 
 
Number patients 
reported 
Median 
(range) 
LNH 
% with 
harvest > 12 
nodes/patient 
2002 report[113] Apr 1999 - Mar 2001 n=3461 11 (0-69) 27.5% 
2004 report[107] Apr 2001 – Mar 2002 n=6823 10 (0-72) 32.8% 
2005 report[129] Apr 2002 – Mar 2003 n=7439 10 (0-130) 35.5% 
2006 report[105] Apr 2003 - Mar 2004 n=6215 NA* 41.0% 
CSCG Welsh Reports 
1st Welsh 
Report[39] 
Apr 2001 - Mar 2002 
Apr 2002 - Mar 2003 
 
n=1157 
 (Apr 2001- Mar 2003) 
8 (NA*) 
7 (NA*) 
NA* 
2nd Welsh 
Report[114] 
Apr 2003 - Mar 2004 n=783 9 (0-119) NA* 
*Data not included in the published report 
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2.2  Aim of Chapter 2 
To investigate the impact of national audit on the national guidelines for lymph 
node harvest in surgical treatment of colorectal cancer in Wales. 
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2.3  Patients and Methods 
 
The study population was all patients undergoing colorectal cancer resection 
in Wales, whose data on lymph node harvest had been submitted for analysis 
as part of the annual Welsh Bowel Cancer Annual Audit between 2005-09.  
During this period there were several adjustments to the configuration of Trust 
and Healthcare Networks in Wales.  It was therefore decided to carry out all 
analyses in this chapter on an individual hospital multi-disciplinary team basis, 
as these have remained constant over the study period.  All 13 Welsh MDTs 
that treat bowel cancer submitted data. In 2005–06 Ysbyty Glan Clwydd were 
unable to participate in the audit but did so in the years 2006-09.  Eleven 
MDTs used Cancer Network Information System Cymru (CANISC) to collect 
and submit their data between 2005-7. Between 2005-7 Gwent Healthcare 
NHS Trust collected information in an ACCESS® database, which was merged 
with the CANISC data into a single all-Wales spreadsheet for analysis.  The 
data for this time period was collected on a Trust basis, which included two 
MDTs and therefore data from the two Gwent MDTs for this period is reported 
separately.  From April 2007 all thirteen MDTs used CANISC to record data.  
 
Patient anonymised data was extracted from CANISC and the Gwent 
Healthcare ACCESS®  database used by the central CANISC team.  It was 
made available for analysis as an Excel password protected spreadsheet 
(Microsoft Corporation) for analysis.  The analysis was undertaken using 
SPSS for Mac version 16.0.   
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The following were calculated on an annual basis: data quality for lymph node 
harvest, defined as the number of patients undergoing surgical resection that 
involved mesenteric excision who had their nodal harvest recorded.  All Wales 
annual median and inter-quartile range of lymph node harvests were 
calculated and compared using the Kruskal-Wallis H test.  Individual unit 
median harvests were calculated for the four consecutive years since 
following the introduction of the twelve node guidance.  The number of units 
meeting national guidelines was calculated and the proportion of the audit 
population whom had a harvest of equal to or greater than 12 nodes was 
calculated and compared using the chi-squared test.  For all statistical 
analyses significance was assumed at the 5% level.  
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2.4  Results 
The study population consisted of 6829 patients who were treated for bowel 
cancer in Wales between 2005 and 2009.  Of these patients 68.7% (4677 
patients) were treated by a surgical procedure that included mesenteric 
resection and an associated lymphadenectomy.  Data on lymph node harvest 
was available for analysis in 4036 (86.3%) of this group (table 2.2).  There 
was year on year variation in the number of cases although the percentage of 
cases having a resection remained similar, as outlined in table 2.2. 
 
Table 2.2 Population of audit by year of study 
Audit Period Total patients 
in audit 
Total patients having 
mesenteric resection 
Number of patients having 
mesenteric resection with 
node harvested recorded 
2005-06 1452 986 (67.9%) 887 (89.9%) 
2006-07 1691 1153 (68.%) 868 (75.2%) 
2007-08 1793 1216 (67.8%) 1053 (86.5%) 
2008-09 1893 1322 (69.8%) 1228 (92.9%) 
Total 6829 4677 (68.5%) 4036 (86.3%) 
 
 
The annual lymph node harvests in the Welsh Audits are presented in the 
figure 2.1 below.  Harvests in 2005/6 were initially below the national 
guidance of 12 but met this standard in 2006/7.  A significant year on year 
increase in national lymph node harvest has been observed.  (Kruskal –Wallis 
H test p<0.001).  The results of individual units are presented in the bar chart, 
figure 2.2, again annual improvements are observed.  
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Figure 2.1 Annual all Wales lymph node harvest 
 
 
 
 
 
Year 2005-6 2006-7 2007-8 2008-9 
Median 
Harvest 
11 12 13 15 
Inter-
Quartile 
Range 
6-16 5-17 9-20 10-20 
 
 
Figure legend 2.1 -  Bar chart showing median harvest by years of audit.  
Dotted reference line corresponds to NICE guidance of 12 nodes.  Data table 
presented beneath graph. 
 
 
 
Kruskal-Wallis H test p<0.001 
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Figure 2.2.  Bar chart showing median lymph nodes examined in each trust 
and all Wales for audit years 2005-09.  
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The number of units achieving the 12 node guidance has again increased 
annually (figure 2.3a).  Immediately after the NICE guidance was issued less 
than 40% of units were compliant, this has risen to more than 80% in the most 
recent time period.   The proportion of patients having resectional surgery who 
had a lymph node harvest >12 nodes have also shown a year on year 
incremental rise from 49% in 2005/6 to 69% in 2008/9 (figure 2.3b). 
 
Figure 2.3a Bar chart of the proportion of units achieving the NICE guidance 
of a median harvest of 12 nodes / patient.  Figures within the bars correspond 
to the actual number of units in each category. 
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Figure 2.3b  Proportion of whole audit population having greater than or 
equal to 12 nodes examined by year of audit.  Data table presented beneath 
the chart. 
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2.5  Principal Findings of Chapter 2 
 
1. The quality of data pertaining to lymph node harvest following CRC 
resection in the Welsh National Bowel Cancer has improved over the 
four year study period. 
 
2. Median national lymph node harvests have improved from non-
compliance with NICE guidance in 2005/6 to a position where median 
national harvests exceed the guidance, with year on year improvement 
observed. 
 
3. At individual MDT level most units have shown year on year increase in 
nodal harvests and the number of units compliant with the national 
guidance has increased. 
 
4. The proportion of patients undergoing surgical resection who have > 12 
nodes examined have increased during the study period.   
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2.6  Discussion 
 
The use of clinical audit to improve performance in health care was first 
recognised in the 19th century by Florence Nightingale.  During the Crimean 
war (1853-1855) Nightingale was appalled by the unsanitary conditions and 
high mortality rates amongst injured soldiers at the medical barracks in 
Scutari.  She, with her team of nurses, improved hygiene and sanitation.  
During this period she kept meticulous records of the outcomes of soldiers 
treated and recorded a reduction in mortality from 40% to 2%.  These records 
were instrumental in overcoming resistance of British doctors to the 
improvements in sanitation and hygiene that Nightingale instituted.  This 
success is recognised as one of the earliest programs of clinical audit 
improving outcomes.  
 
In 1863 Nightingale had returned to London and commented that comparative 
audit was necessary to improve outcomes in healthcare across the city, 
however she also acknowledged the difficulties of data collection [130], 
 
“in scarcely any instance have I been able to obtain 
hospital records fit for any purpose of comparison” 
(Nightingale 1863)[130] 
 
In the one hundred and forty years that followed Nightingale’s publication 
little progress was made with establishing national databases on which 
comparative audit could be performed.  However, the Bristol Enquiry into 
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Paediatric Cardiac Surgery Mortality changed this. The subsequent report 
[102] of this enquiry made several recommendations including that there, 
“must be agreed and published standards of clinical care for healthcare 
professionals to follow” and that, “there must also be a system of external 
surveillance to review patterns of performance over time”. 
 
Since the Bristol enquiry the number of national databases for the purpose of 
comparative audit have increased dramatically, incorporating many aspects 
of healthcare, with cancer management and surgical outcomes the most 
commonly audited areas [131].  Whilst there are a large number of databases 
covering wide variety of conditions, there have been problems with the 
quality of data being entered, both in terms of missing data and its accuracy 
[131-134].  
 
The UK wide NBOCAP audits [103, 105, 107, 113, 118, 135] have 
experienced problems with poor data completeness across all variables 
examined in the audit.  In these national audits overall data quality has 
improved with time but there remains inter-unit variability and overall 
completeness of submissions is lower than the authors desire.  In Wales, the 
CSCG have sponsored annual WBCA reports that have reported ever 
increasing data completeness in recent years[39, 115, 116, 136]. A 
significant factor promoting data collection in Wales was the issuing by the 
Wales Assembly Government of the Welsh Health Circular [WHC(2008)054] 
that mandated the use of CANISC for data collection by trusts.  The data 
completeness for nodal harvest reported in this chapter reflects this 
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mandation of data collection, with 93% of patients undergoing a resection in 
Wales having their nodal harvest recorded in the most recent audit period.  
 
There are other reasons why the data submitted to recent WBCAs has been 
more complete than in the NBOCAP/ACPGBI national counterparts. The 
number of trusts involved has allowed a more individual approach in Wales.  
Over this period, if initial analyses have shown missing data, lead clinicians 
of MDTs have been contacted to request improved data and the re-submitted 
data has been re-analysed to produce the final WBCA reports.  This process 
of requesting improved data is almost certainly one reason why the Welsh 
data is more complete than the NBOCAP / ACPGBI national counterpart.  
Experience from the UK cardiac surgery audit has shown that a process of 
validation, monitoring and feedback can improve data quality [137].  In this 
paper Fine et al. [137] carried out a retrospective study of the data recorded 
in the database, which was then cross referenced with the data available 
from the patients’ case notes, finding that data was missing in 25% of 
database entries compared to 1% in the patient notes.  Units were then given 
feedback of missing data, which improved subsequent data submissions to a 
point where only 9% of submissions missing [137].  Whilst it is believed that 
the request for improved data from MDTs with poor submissions in the 
WBCA has been important in improving data quality, there are other potential 
influences that may have improved performance.  There have been several 
educational meetings organised by the Welsh CSCG.  These meetings have 
been attended by both cancer services clerical staff and clinicians.  At these 
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meetings the need for improved data quality has been frequently highlighted 
which has potentially raised awareness of the need for high quality data.  
 
Compliance with National Guidelines 
 
Prior to the NICE nodal guidance in 2004 [26] nodal harvests in the both the 
ACPGBI / NBOCAP  and WBCA audits were consistently lower than the 12 
node guidance.  The data presented in this chapter has shown that in the first 
year after the guidance the median harvest for the whole of Wales was 11 
nodes/patient.  At the same time the majority of units in Wales also had a 
median harvest below 12.  In the second year after the guidance the target 
harvest was achieved in Wales. Thereafter there has been an annual 
increase in both median harvests for the whole of Wales and the number of 
units and patients having 12 or more nodes examined.  The results of Ysbyty 
Maelor Wrexham presented in this chapter are also worthy of further 
comment, this unit has consistently achieved a median nodal harvest in 
excess of 25 nodes.  Following personal communication with this units MDT 
it is believed that this is due to the diligence of a single pathologist.   
 
There are several plausible reasons to explain the national improvement 
observed.  The very existence of national guidelines for the number of nodes 
to be harvested probably has contributed to this improvement.  Data from 
analyses of the United States SEER data mirror the findings of this chapter; 
that harvests increase when guidelines are introduced.  An analysis of the 
United States SEER data between 1988 and 2000, pre-dating the 2001 
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National Cancer Institute (NCI) guidance that 12 nodes should be examined 
in node negative disease [29], found that the most common number of lymph 
nodes assessed in colon cancer was zero and that the median harvest was 
nine nodes [138]. Since the NCI guidance was published, a similar analysis 
of SEER data [82], which included patients diagnosed up to 2005 showed 
that the mean number of nodes sampled in both colonic and rectal cancer 
has increased dramatically.  In the UK the NBOCAP audits have reported 
similar improvements in nodal harvest since the introduction national 
guidance[103, 105, 107, 118]. These results, in conjunction with the results 
presented in this thesis, support the hypothesis that National Guidance can 
improve clinical performance, although it must be acknowledged that this 
evidence in circumstantial. 
 
The existence of the WBCA itself may have contributed to the improved 
harvest reported in this chapter is.  In the paper, “Principles for Best Practice 
in Clinical Audit” published by NICE [139], audit has been defined as,  
 
“a quality improvement process that seeks to improve patient care and 
outcomes through systematic review of care against explicit criteria. Aspects 
of the structure, processes, and outcomes of care are selected and 
systematically evaluated against explicit criteria”[139] 
 
The WBCA reports have been published on the world wide web on the 
CSCG website and each MDT has been sent a copy of the report and 
encouraged to undertake an internal review of performance against national 
 103 
standards and other units in Wales. The audit results are now trust 
identifiable, trusts were made aware that open reporting would take place 
and this may have contributed to the improved results.  In addition, the 
results of the WBCA have been publicised at the CSCG sponsored 
educational meetings throughout Wales.  Whilst there have been no specific 
actions taken against Trusts failing to comply with the 12 node guidance, the 
CSCG for Wales highlighted its perceived importance by including nodal 
harvest as one of its key, “clinical indicators of bowel cancer care” in its 2005-
2007 report [115].  
 
The Bristol enquiry [102] has led to a dramatic increase in clinical audit within 
the UK.  A Cochrane review published since the Bristol enquiry [102] 
examined the effect of audit and feedback on healthcare outcomes, it 
concluded that audit can be effective in improving clinical practice [140].  
Relating this to the improvements in nodal harvests reported in this chapter, it 
is likely that the annual completion of the audit cycle through the existence of 
the WBCA may have impacted on the increased harvests reported in this 
chapter.   
 
The role of feedback on practice was studied in a systematic review reported 
by Mugford et al. [141].  One of the findings of this review was that 
minimising the time interval between collection of data collection and 
reporting results was important in improving performance.  Whilst the WBCA 
reports annually, there is a time lag between completion of data collection 
and publication of the report, typically at least 12 months.  The effect of this 
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publication time lag is that year on year improvement may not be directly 
attributable to the previous years audit results.  However, the consistent 
improvement in yield over the four years presented in this chapter suggests 
that the improved performance may in part be due to the effect of audit.  This 
is supported by the results of a recent study from Canada [142], which 
reported that dissemination of audit results showing suboptimal harvest 
improved performance in a single health district.    
 
Whilst the introduction of national guidelines and the effect of audit may both 
have influenced the increase in nodal harvests observed, there are other 
potential factors that should to be considered.  “Lymph node harvest” in 
colorectal cancer treatment as a topic of research has become relatively 
fashionable in the colorectal literature.  If the phrase, “lymph node harvest 
colorectal cancer” are entered into Pubmed [143] for the period 1st January 
2004 to 31st December 2010 fifty eight citations are returned, an identical 
search for the preceding six year period 1st January 1998 to 31st December 
2003 returns twelve citations. This increase in publications pertaining to 
lymph node harvest may have increased clinician awareness to the potential 
importance of harvest, which in turn may have influenced practice to increase 
nodal yield. 
 
The improved harvests may also be influenced by the results of sub-group 
analyses of large chemotherapy trials.  These have identified inferior survival 
when a node negative status is assigned on the basis of examination of less 
than 12 nodes confers worse survival [144].  Consequently it has been 
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recommended that patients assigned a node negative status on the basis of 
sampling less than 12 nodes should be considered ‘high risk’ and as such be 
considered for adjuvant chemotherapy [144-147]. This guidance, in the 
author’s experience, is often the subject of debate in the colorectal MDT 
meeting, which frequently culminates in a request for the pathologist to 
search for more nodes.  Whilst difficult to quantify this internal pressure from 
within MDTs may also have contributed to increased nodal harvests. 
 
Sub-specialisation in surgery has been associated with improved outcomes 
[148-151]. It is therefore possible that the increasing surgical sub-
specialisation in coloproctology has contributed to the increased harvest.  
Data from the US supports this hypothesis where increasing surgeon volume 
[47] and colorectal fellowship training [48] can confer higher nodal yields than 
those achieved by low volume non-colorectal surgeons.  Whilst this may 
have impacted on the results in the US, fundamentally there are differences 
in the way in which sub-specialisation has occurred in the UK, compared to 
the US.  In the UK almost all General Surgeons now have a sub-speciality 
interest, in which most of the elective surgery performed by that surgeon is 
carried out. In the US this sub-specialisation has not occurred as rapidly. 
Publications emanating from UK units, with similar study time periods to this 
chapter, and the data in chapter one of this thesis have concluded that sub-
speciality of operating surgeon does not independently impact on lymph node 
harvests [40, 49].  Whilst data about the sub-speciality of the operating 
surgeon is unavailable from the WBCA, it is not believed that sub-
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specialisation has had a marked impact on the results presented in this 
chapter. 
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2.7  Conclusion Chapter 2 
 
The principal findings of this chapter are that the WBCA has experienced an 
annual improvement in data completeness, unit and national nodal harvests 
and compliance with national guidelines.  The reasons for this improvement 
are not fully understood but could include publication of national guidelines, 
national comparative audit, open reporting and increased research into nodal 
harvests following colorectal resection.  The relative importance of each of 
these factors on the improved performance is not known but it is likely that the 
reasons are multi-factorial with each factor contributory. 
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Chapter 3 
Impact of nodal harvest on survival following colorectal cancer 
resection in Wales
 109 
3.1  Introduction 
 
The rationale for maximising the number of lymph nodes harvested following 
colorectal resection for cancer is the perception that lower lymph node 
harvests risk of under-staging a patients’ disease.  Previous studies of node 
negative colorectal cancer patients (Dukes’ stage A and B) have found that 
lower lymph node harvests are associated with worse survival[10, 12, 16, 21, 
23, 38].  The situation in patients with node positive disease (Dukes’ stage C) 
is less clear, with some studies reporting worse survival at lower harvest 
levels[10, 12, 16], whilst others have found no difference[14, 21, 38].  
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3.2  Chapter Aims 
 
The aims of this chapter were:  
i.  To examine the impact that nodal harvest had on survival of patients 
with Dukes’ stage B and C colorectal cancer in the WBCA 
ii.  To establish variables that independently predicted survival in 
Dukes’ stage B and C colorectal cancer in the WBCA  
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3.3  Patients and Methods 
 
The study population was the 1453 patients diagnosed with bowel cancer in 
Wales between April 2005 and March 2006, whose data had been reported to 
CANISC and populated the WBCA audit report for that year [115].  This year 
was chosen for this analysis because all patients who remained alive had 
completed a minimum of five year follow up from the date of diagnosis at the 
time on analysis.  In this period twelve of the thirteen MDTs in Wales that 
treated bowel cancer participated in the WBCA.  Death data was obtained by 
linkage of three databases:  CANISC, ONS (Office for National Statistics) and 
WICSU (Welsh Cancer Intelligence Surveillance Unit) using NHS number as 
the common identifier.  WICSU receives death certificate data from ONS. In 
May of 2011 WICSU provided survival data for all relevant CANISC patients 
and used NHS numbers to provide an anonymised excel spreadsheet. 
 
Patients treated without surgical resection were excluded from analysis, as 
they did not undergo a lymphadenectomy, leaving 1035 patients who had 
undergone surgical resection with associated mesenteric resection.  Potential 
inaccuracies in Dukes’ stage reported to the audit were identified and 
amended in the following way; patients identified as having liver or lung 
metastases on their staging CT scan result had their Dukes’ stage amended 
to stage D, irrespective of what stage had been recorded in the field “clinico- 
pathological Dukes’ stage”, twenty-five records were amended in this way.  
Dukes’ stage D patients were then excluded from survival analyses, in total 67 
patients undergoing surgical resection were Dukes’ stage D, leaving 967 
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patients for further analysis.  The aim of this study was to compare survival of 
patients staged as Dukes’ B and C, therefore patients staged as Dukes’ A 
were excluded (125 patients).  Rectal cancer patients treated with pre-
operative long-course chemoradiotherapy, which may have altered 
pathological stage, were also excluded (10 patients).  In a further 122 patients 
no data on Dukes’ stage or lymph node harvest data had been submitted to 
the audit, even though they were recorded as having had resectional surgery, 
these patients were therefore also excluded.  This left 711 patients for 
analysis.   
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3.4  Statistical analysis 
 
The median harvest and inter-quartile range (IQR) of patients with Dukes’ 
stage B and C cancer was calculated and compared with the Mann-Whitney U 
test.  The survival of all patients with Dukes’ stage B and C colorectal cancer 
was calculated, using life table analyses, and compared with the log-rank test.  
The impact of lymph node harvest on survival of patients with Dukes’ stage B 
and C disease, with variable lymph node harvests, was compared 
sequentially using the log-rank test.  Speculative univariate analysis of 
variables reported to the audit, which may have impacted on survival, was 
performed on all patients with Dukes’ stage B and C together, on patients with 
stage B only and on patients with stage C only using log-rank tests.  In 
addition in Dukes’ stage C patients lymph node ratio was calculated for all 
patients, except for the 19 patients (5.2%) who did not have data on the 
number of positive lymph nodes submitted to the audit. Survival was 
compared between the lymph node ratio groups.  Lymph node ratio was 
defined as the total number of involved nodes divided by the total number of 
nodes harvested.  Factors that were significant variables for survival on uni-
variate analysis were then entered into a backward multivariate cox-
regression model to determine factors that independently predicted survival in 
each group.  Significance for all calculations was assumed at the 5% level (p 
<0.05).  Data was collected on a Microsoft Excel® (Washington, USA) and 
analysed using SPSS® for Mac version 18.0 (New York, USA).
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3.5  Results 
 
There were 344 Dukes’ stage B and 366 stage C patients in the study with a 
median follow up of 69 months in surviving patients.  The overall median 
lymph node harvest was 12 nodes per patient (IQR 8-17).  Median harvest for 
Dukes’ stage B patients was 11 nodes (IQR 7-16) and for Dukes’ stage C was 
12 nodes (IQR 8-18), Mann-Whitney U p=0.014.  The Kaplan-Meier plots of 
overall survival in Dukes’ B and C patients are presented below in fig 3-1.   
 
 
Figure 3-1 – Overall survival of Dukes’ stage B and C patients  
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The overall five-year survival of Dukes’ stage B patients was 62% against 
45% in those staged as Dukes’ stage C, log-rank p<0.001. Survival was then 
compared between Dukes stage B, divided into sub-groups sequentially 
according to their lymph node harvest (Table 3-1).  Identical analysis was then 
carried out for stage C patients.  In patients staged as Dukes’ B, a statistically 
significant survival difference was observed when the cohort was split 
between harvests of <9 / >9 incrementally up to <14 / >14 nodes.  Below and 
above these levels there was no statistical difference in survival.   In patients 
staged as Dukes’ C survival differences were observed when the cohort was 
spilt between < / >7 and < / >8 nodes.  Above this level no difference in 
survival was observed. 
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Table 3-1 – Survival comparison of patients with Dukes’ stage B and C 
disease with a variable lymph node harvest  
 
Dukes’ stage and 
harvest 
 
n patients 
 
Five year survival 
 
 
Log rank  
B ≥7 LN 
  
B <7 LN 
272 
 
72 
63% 
 
58% 
p=0.186 
B ≥8 LN         
 
B <8 LN 
256 
 
88 
63% 
 
60% 
p=0.265 
B ≥9 LN 
 
B <9 LN 
233 
 
111 
65% 
 
55% 
p=0.029 
B ≥10 LN 
 
B <10 LN 
214 
 
130 
66% 
 
55% 
 
p=0.011 
B ≥11 LN 
 
B <11 LN 
191 
 
153 
68% 
 
56% 
p=0.008 
B ≥12 LN 
 
B <12 LN 
167 
 
177 
70% 
 
56% 
 
p=0.003 
B ≥13 LN 
 
B <13 LN 
143 
 
201 
69% 
 
57% 
 
p=0.012 
B ≥14 LN 
 
B <14 LN 
131 
 
213 
70% 
 
57% 
 
p=0.017 
B ≥15 LN 
 
B <15 LN 
114 
 
230 
68% 
 
60% 
 
p=0.078 
B ≥18 LN 
 
B <18 LN 
77 
 
267 
69% 
 
60% 
 
p=0.075 
 
C ≥7 LN 
  
C <7 LN 
310 
 
56 
47% 
 
28% 
 
p=0.001 
C ≥8 LN         
 
C <8 LN 
289 
 
77 
47% 
 
33% 
 
p=0.011 
C ≥9 LN 
 
C <9 LN 
265 
 
101 
45% 
 
42% 
 
p=0.605 
C ≥10 LN 
 
C <10 LN 
246 
 
120 
46% 
 
40% 
 
p=0.304 
C ≥12 LN 
 
C <12 LN 
213 
 
153 
47% 
 
41% 
 
p=0309 
C ≥15 LN 
 
C <15 LN 
146 
 
220 
43% 
 
45% 
 
p=0.559 
C ≥18 LN 
 
C <18 LN 
109 
 
257 
44% 
 
45% 
 
p=0.897 
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3.6  Variables impacting on survival of all Dukes’ stage B and C patients 
 
Speculative uni-variate analyses of factors, which may have impacted on the 
survival of the whole cohort, are presented in table 3-2. 
 Table 3-2 Uni-variate analyses of factors that may have impacted on survival 
of the whole study population 
Factor Data 
Quality* 
5 year 
survival 
Log-rank p 
value 
 Age <50 
50-59 
60-69 
70-79 
>80 
 
 
100% 
70% 
64% 
63% 
47% 
37% 
 
 
p<0.001 
Sex  Male 
Female 
100% 50% 
57% 
p=0.163 
Unit of operation 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
100% 48% 
60% 
52% 
54% 
55% 
56% 
53% 
49% 
52% 
52% 
57% 
54% 
 
 
 
 
 
p=0.370 
NCEPOD mode of 
surgery  
Elective 
Scheduled 
Urgent 
Emergency 
92.3% 61% 
57% 
42% 
38% 
 
p<0.001 
ASA**  I 
II 
III 
IV 
V 
43.5% 74% 
59% 
44% 
24% 
No patients 
p<0.001 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System   
Table 3-2 continued overleaf 
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Table 3-2 (continued) - Uni-variate analysis of factors that may have impacted 
 on survival of the whole study population 
 
Factor Data 
Quality* 
5 year 
survival 
Log-rank p 
value 
Type of operation Right Hemi 
Left Hemi 
Sigmoid colectomy 
Anterior Resection 
APER 
Hartmann’s 
Total colectomy 
100% 48% 
55% 
53% 
66% 
54% 
30% 
52% 
 
 
 
p<0.001 
Colonic or rectal Colonic 
Rectal 
100% 54% 
58% 
p=0.220 
Number of nodes 
examined 
0-6 
7-12 
13-18 
18+ 
100% 46% 
53% 
55% 
58% 
p=0.027 
Number of nodes 
involved 
1-3 
4-6 
7-9 
10-12 
12+ 
100% 57% 
35% 
34% 
27% 
34% 
 
 
p<0.001 
T stage  T1 
T2 
T3 
T4 
81.3% 100% 
68% 
61% 
32% 
p<0.001 
Dukes’ stage B 
C 
100% 62% 
44% 
p<0.001 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System 
 
Factors found to have a significant impact on survival (p<0.05) on uni-variate 
analysis were entered into a backward Cox – regression multivariate model to 
determine factors independently predictive of survival. The following factors 
independently predicted survival:  
 Advancing age (Hazard ratio 1.038 per decade increase, 95% 
C.I 1.028-1.049, p<0.001) 
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 Number of positive lymph nodes (Hazard ratio 1.091, 95% C.I 
1.060-1.032, p<0.001) 
 Number of lymph nodes examined (Hazard ratio 0.981 per node, 
95% C.I 0.968-0.995, p=0.006) 
 Emergency operation (Hazard ratio 1.006, 95% C.I 1.001 – 
1.010, p=0.011) 
 Higher Dukes’ stage (Hazard ratio 1.294, 95% C.I 1.040-1.731, 
p=0.02) 
 Higher T stage (Hazard ratio 1.003, 9.5% C.I 1.001-1.005, 
p=0.042).   
 ASA grade (p=0.939) and type of operation (p=0.466) were 
excluded from the model and did not therefore independently 
predict survival.  
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3.7  Variables impacting on survival of Dukes’ stage B patients only 
 
Speculative uni-variate analyses of factors, which may have impacted on 
survival of Dukes’ stage B are presented in table 3-3. 
Table 3-3 Uni-variate analyses of factors that may have impacted on survival of 
Dukes’ stage B patients 
 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System 
Table 3-3 continued overleaf 
Factor Data 
Quality* 
5 year 
survival 
Log-rank p 
value 
 Age <50 
50-59 
60-69 
70-79 
>80 
 
 
100% 
No patients 
70% 
70% 
61% 
45% 
 
 
p<0.001 
Sex  Male 
Female 
100% 56% 
69% 
p=0.022 
Unit of operation 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
100% 45% 
50% 
59% 
61% 
65% 
62% 
57% 
48% 
57% 
58% 
63% 
49% 
 
 
 
 
 
p=0.760 
NCEPOD mode of 
surgery  
Elective 
Scheduled 
Urgent 
Emergency 
93.9% 69% 
63% 
58% 
43% 
 
p<0.001 
ASA**  I 
II 
III 
IV 
43.6% 87% 
63% 
51% 
22% 
 
 
p<0.001 
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Table 3-3 (continued) Uni-variate analyses of factors that may have impacted 
on survival of Dukes’ stage B patients 
 
Factor Data 
Quality* 
5 year 
survival 
Log-rank p 
value 
Type of operation Right Hemi 
Left Hemi 
Sigmoid colectomy 
Anterior Resection 
APER 
Hartmann’s 
Total colectomy 
100% 58% 
63% 
62% 
72% 
63% 
43% 
63% 
 
 
p=0.166 
Colonic or rectal Colonic 
Rectal 
100% 61% 
63% 
p=0.573 
Number of nodes 
examined 
0-6 
7-12 
13-18 
18+ 
100% 59% 
56% 
65% 
74% 
 
p=0.049 
T stage  T1 
T2 
T3 
T4 
79.4% No patient T1N0 
44% 
70% 
47% 
 
p=0.001 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System 
 
Factors found to have a significant impact on survival (p<0.05) on uni-variate 
analysis were entered into a backward Cox – regression multivariate model to 
determine factors independently predictive of survival. The following factors 
independently predicted survival of Dukes’ stage B patients:  
 Advancing age (Hazard ratio 1.447 per decade increase, 95% 
C.I 1.307-1.802, p<0.001) 
 NCEPOD mode of surgery (Hazard ratio 1.001, 95% C.I 1.000 -
1.002, p<0.001) 
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 Number of lymph nodes examined (Hazard ratio 0.973 per node 
increase, 95% C.I 0.949-0.997, p=0.003)  
 Female patient gender (Hazard ratio 0.604, 95% C.I 0.477-
0.949, p=0.009)   
 ASA grade (p=0.237) and T stage (p=0.190) were excluded from 
the model and did not therefore independently predict survival.  
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3.8  Variables impacting on survival of Dukes’ stage C patients only 
Speculative uni-variate analyses of factors, which may have impacted on 
survival of patients staged as Dukes’ C are presented in table 3-4.  
 
Table 3-4 Uni-variate analyses of factors that may have impacted on survival of 
Dukes’ stage C patients 
Factor Data 
Quality* 
5 year 
survival 
Log-rank p 
value 
 Age <50 
50-59 
60-69 
70-79 
>80 
 
100% 
58% 
60% 
57% 
34% 
28% 
 
 
p<0.001 
Sex  Male 
Female 
100% 45% 
45% 
p=0.634 
Unit of operation 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
 
 
100% 
43% 
80%*** 
44% 
49% 
50% 
41% 
31% 
43% 
46% 
39% 
45% 
44% 
 
 
 
 
 
p=0.346 
NCEPOD mode of 
surgery  
Elective 
Scheduled 
Urgent 
Emergency 
90.7% 52% 
52% 
27% 
32% 
 
 
p<0.001 
ASA**  I 
II 
III 
IV 
V 
43.3% 63% 
56% 
37% 
25% 
No patients 
 
 
p=0.012 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System 
*** Only 5 cases were Dukes C in this unit and 4 survived long-term 
Table 3-4 continued overleaf 
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Table 3-4 (continued) Uni-variate analyses of factors that may have impacted 
on survival of Dukes’ stage C patients 
 
Factor Data Quality* 5 year 
survival 
Log-rank p 
value 
 
Type of operation Right Hemi 
Left Hemi 
Sigmoid colectomy 
Anterior Resection 
APER 
Hartmann’s 
Total colectomy 
100% 40% 
47% 
46% 
60% 
47% 
21% 
31% 
 
 
 
p=0.002 
Colonic or rectal Colonic 
Rectal 
100% 42% 
52% 
p=0.039 
Number of nodes 
examined 
1-6 
7-12 
13-18 
18+ 
100% 29% 
49% 
45% 
47% 
 
p=0.007 
Number of nodes 
involved 
1-3 
4-6 
7-9 
10-12 
12+ 
100% 53% 
35% 
35% 
27% 
25% 
 
p<0.001 
Lymph Node Ratio 0 - 0.24 
0.25 – 0.5 
0.51 – 0.75 
0.76 – 1.0 
94.8% 51% 
46% 
41% 
11% 
 
p<0.001 
T stage  T1 
T2 
T3 
T4 
83.1% 50% 
75% 
51% 
24% 
 
p<0.001 
* Data Quality defined as the percentage of patients with data for this variable submitted to the audit  
** ASA = American Society of Anaesthesiologists Grading System 
*** Only 5 cases were Dukes C in this unit and 4 survived long-term 
 
Factors found to have a significant impact on survival (p<0.05) on uni-variate 
analysis were entered into a backward Cox – regression multivariate model to 
determine factors independently predictive of survival. The following factors 
independently predicted survival of Dukes’ stage C patients:  
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 Advancing age (hazard ratio 1.036/ decade (95% C.I - 1.023-
1.050), p<0.001) 
 Lymph node ratio, defined as the number of involved lymph 
nodes divided by the total lymph node harvest,  (hazard ratio 
1.308 (95% C.I – 1.195 – 1548, p<0.001).    
Number of involved nodes, number of lymph nodes examined, ASA grade, 
operation type, NCEPOD mode of surgery, tumour site and T stage were 
excluded from the model and did not therefore independently predict survival.  
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The Kaplan – Meier curves of survival according to lymph node ratio are 
presented in figure 3-2 and demonstrate the poor prognosis of patients with 
higher LNR.  
Figure 3-2.  Kaplan-Meier plot of survival according to LNR (lymph node 
ratio) 
 
 
 Data table supporting figure 4-2 
 
 
 
 
 
 
 
 
 
 
 
Number at risk 
Survival (months) 
 
 
LNR  
0 
 
 
12 
 
24 
 
36 
 
48 
 
60 
 
0 - 0.24 191 157 138 122 105 99 
0.25 - 0.49 70 56 49 41 36 33 
0.5 - 0.74 48 35 28 23 21 20 
0.75 - 1.0 34 19 12 7 5 4 
 127 
 
3.9  Discussion 
 
This chapter has studied the factors that have impacted upon survival of 
patients, with Dukes’ stage B and C colorectal cancer (CRC), treated in Wales 
between April 2005 and March 2006. The principal findings, in relation to this 
thesis, are that five year survival in Dukes’ stage B (node negative) cancer is 
independently predicted by higher nodal harvests and that lymph node ratio 
(number of involved nodes: total node harvest)  independently predicts 
survival in Dukes’ stage C (node positive) cancer. 
 
The overall five year survival of patients with Dukes’ stage B disease treated 
in Wales in the study period was 62%, this is lower than the 77% five year 
survival reported for patients diagnosed in England between 1996-2002[1].  
The 45% five year survival of Dukes’ stage C patients in this chapter, 
however, is similar to the 47% reported in England between 1996-2002[1].  
Worse survival for Welsh patients with bowel cancer, compared their English 
and European counterparts, has previously been reported [152].  However, 
why this difference is so marked in stage B disease reported in this chapter is 
not known.  
 
Patients staged as Dukes’ stage B in this chapter had a significant survival 
advantage at higher harvests when the cohort was split between harvests of 
<9 / >9 incrementally up to <14 / >14 nodes, with improved five year survival 
of between 10 and 14%.  These data support the findings of previous studies 
that have similarly found that lower harvests in node negative CRC confer a 
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worse prognosis [9, 10, 12, 15, 16, 19, 21-24, 38, 51].  The reasons for this 
improvement could relate to stage migration, a more radical 
lymphadenectomy or lymph node hypertrophy, secondary to the patients own 
immune system fighting disease, making nodal identification easier.  These 
reasons and the results of these previous studies have been discussed in 
detail in the introduction section of this thesis.  
 
The data presented for Dukes’ stage B patients also imply that the current 
twelve node national guidance [26-28] for lymph node retrieval may be too 
low,  suggesting that at least fourteen nodes need to be harvested to more 
confidently assign a patient a node negative status.  However, the finding that 
there was a statistically non-significant survival benefit in Dukes’ stage B 
patients beyond a split of fourteen nodes could represent a type II statistical 
error.  This result endorses the previous recommendations of Goldstein et al. 
[9] and Cserni et al. [13] that as many nodes as possible should be evaluated 
after CRC resection.  The current NICE guidance of 12 nodes for lymph node 
retrieval [26] was published in 2004.  Data presented in chapter two of this 
thesis reported that prior to the NICE guidance average national performance 
was less than the twelve node recommendation, since the guidance was 
issued, performance has improved.  The results presented in this chapter 
advocate that the 12 node guidance should now be revised to a higher level.  
The worse survival in node negative patients at lower lymph node harvests 
also supports the opinion of some that adjuvant chemotherapy should be 
offered to node negative patients with a harvest of less than twelve 
nodes[144-147].    
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Survival following separating the Dukes’ C (node positive) cohort according to 
nodal harvest, found that lower harvests were associated with a survival 
disadvantage.  Below a level of <9 / >9 nodes there was a survival difference 
but above this level there was no difference.  Previous studies have reported 
improved survival at higher levels of nodal harvests when cohorts of node 
positive patients have been analysed in a similar method to this chapter[10, 
12, 13, 16, 19, 51].  However, these studies have observed differences in 
survival at higher separation points than the </ > 9 node level found in the 
present study.    There have also been several studies that have found that 
nodal yield does not influence survival in node positive cancer [14, 21, 22].  
The worse survival at very low level of harvests in the current study could be 
explained by inadequate surgery, with an incomplete lymphadenectomy failing 
to clear a patient’s disease.  Alternatively it may be that tumour-host 
interaction has impacted on these results, with the inability of the host to 
mount a response leading to lower harvests because the nodes are not 
enlarged.  This failure to mount a response would consequently negatively 
impact on the host’s ability to resist the disease process, conferring worse 
survival [22, 111].  The less marked differences in survival according to lymph 
node harvest in Dukes’ C cancers against Dukes’ B imply that stage migration 
is responsible for the greater survival differences in node negative disease.  
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This chapter has found advancing age to be an independent predictor of 
survival following colorectal cancer resection in the whole study population 
and in separate analyses of Dukes’ stage B and C disease. The finding that 
older age at diagnosis negatively impacts on survival is well reported [16-18, 
153, 154].   In one large secondary analysis of pooled data from three 
chemotherapy randomised control trials, Sergeant et al. [155] found that 
patients over the age of 70 had a seven fold increased risk of non-cancer 
related death than patients aged less than 50. The mortality data provided by 
WICSU for analysis in this chapter included all causes of death, as opposed 
to cancer specific survival.  It is therefore likely that the poorer prognosis 
observed with advancing age in this chapter is a reflection of the general 
increased risk of death in elderly patients from other causes.  
 
Analysis of the whole study population found the number of positive nodes, 
advancing T and Dukes’ stage, the number of nodes examined and 
emergency surgery independently predicted survival. The first three are 
pathological variables that represent more advanced disease.  Their impact 
on survival is therefore unsurprising, with each of these variables well 
reported to negatively impact on survival from colorectal cancer [2, 8, 10, 16, 
18, 19, 156]. The finding that lymph node harvest is a strong independent 
predictor of survival supports the importance of maximising nodal harvest 
after colorectal resection.  Emergency surgery for colorectal cancer has also 
been widely recognised surgery to be a negative predictor of long term 
survival [25, 91, 153, 157]. 
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In node negative cancer (Dukes’ B) female sex was found to confer an 
independent survival benefit, although no difference in survival was observed 
in node positive (Dukes’ C) disease.  Improved female cancer specific and 
general survival has been frequently reported [158-161] following colorectal 
cancer.  This may be due to the protective effects of oestrogens against 
microsatellite unstable cancers [159].  However, previous reports have found 
differences in survival in both node negative and node positive disease 
stages, the reasons for the variation from the norm observed in the current 
chapter are unknown.  
 
In node positive disease (Dukes” C) the only independent predictors of 
survival were age and lymph node ratio (LNR).  It has been well documented 
that higher numbers of lymph node metastases confer a worse survival [8, 15, 
16, 19, 24, 162, 163], consequently this forms the basis of the nodal stage 
differentiation in the TNM staging system (see appendix 2), with “N1” having 
1-3 nodes involved and “N2” having >4 nodes involved.  Several recent 
studies have evaluated LNR as a prognostic indicator.  Berger and colleagues 
[162] were the first to report on this, finding that LNR independently predicted 
survival of node positive colorectal cancer.  Subsequently, Wang et al. [32] 
have analysed 24.477 node positive patients from the SEER database, 
splitting LNR into four sub-groups, they found after adjustment for age, race, 
number of positive lymph nodes and total number of lymph nodes harvested 
that LNR was an independent predictor of survival.  De Ridder et al. [164], 
again using SEER data on over twenty six thousand patients, compared the 
prognostic value of splitting patients into two LNR groups (LNR1= <0.4 and 
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LNR 2 = >0.4) against the UICC pN1 and pN2 categories.  They found that 
the prognostic separation was greater with the LNR staging system.  They 
therefore concluded that it was a more prognostic indicator than pN1/2 
staging system.  In this chapter LNR was the only lymph node related variable 
that independently predicted survival in node positive disease, these data in 
conjunction with previous studies suggest that LNR should be adopted into 
future staging systems for node positive cancer. 
 
There are some limitations with the data analysed in this chapter, which must 
be acknowledged. The data was submitted to CANISC and used to populate 
the WBCA report for this year [115].  In this audit year (2005-6) only twelve of 
the thirteen MDTs that treat bowel cancer participated in the audit.   Although 
this has reduced the population size of the study it is not believed that this will 
have influenced the results as the case mix treated by the non-submitting unit 
should not be different from the remainder of units analysed.  Data 
submission in 2005-6 was voluntary, it is therefore possible that not all cases 
of colorectal cancer in Wales in that year have been analysed.  However, 
case ascertainment to the audit against colorectal cancer registrations with 
WICSU for this period [115] showed that, including the unit that did not 
participate, 84% of patients treated for bowel cancer in Wales in 2005-6 were 
represented in this chapter.  If the unit that did not participate is excluded from 
analysis, 92% of patients with bowel cancer diagnosed in 2005-6 and 
registered with the cancer registry were included in data analysed in this 
chapter.  It is therefore unlikely that missing patients will have significantly 
influenced results.   
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Whilst a potential strength of the data is its prospective capture, there have 
been problems with data accuracy and the amount of missing variables 
reported to the WBCA.  This is exemplified by the data accuracy within the 
audit field, “Clinico-pathological Dukes’ stage”.  This field has been 
problematic for the WBCA with patients with liver or lung metastases miss-
staged as Dukes’ stages A-C, as observed in the 25 cases amended in this 
chapter.  This error is believed to arise because non-clinical MDT co-
ordinators may submit the data with little clinician involvement.  If this is 
representative, it is possible that there may have been other errors in data 
submission, which may have impacted on the results presented.  Another 
area of difficulty experienced by the WBCA has been the number of missing 
fields in the audit.  This is supported by the results of this chapter that found 
122 (12%) of patients having a resection had no Dukes’ stage or lymph node 
harvest recorded and that only 44% of patients undergoing resection had their 
ASA score submitted.  The poor quality of ASA returns may have impacted on 
the analyses of variables predicting survival.  ASA score can be considered 
as a surrogate marker of medical co-morbidity [165], it was therefore a 
surprising result that it did not independently predict survival.  Increasing ASA 
score was found on all uni-variate analyses to predict worse survival but was 
excluded by the multi-variate model in all cases.  This may have lead the 
model to erroneously dismiss ASA as an independent predictor.   
 
The data collected for the WBCA has a limited number of variables, it is 
therefore likely that there are other independent predictors of survival that 
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have not been examined in the survival analyses.  This may be particularly 
pertinent for node negative patients who may have other poor prognostic 
features, such as extra-mural vascular invasion, poor primary tumour 
differentiation or serosal involvement that have been shown to negatively 
impact upon survival and consequently have been advocated as indications 
for adjuvant chemotherapy [27, 144, 146, 166-168].  Data on theses variables 
was not collected by the WBCA in the year studied in this chapter.    In 
addition to these tumour related variables not collected by the WBCA, data on 
adjuvant chemotherapy use was also not collected, the use of which is likely 
to have impacted on survival and could have impacted upon the results 
presented.    
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3.10  Conclusions 
 
This chapter has found that increasing nodal harvest in Dukes’ B (node 
negative) colorectal cancer independently predicts survival.  The results 
suggest that a harvest of at least fifteen nodes is required to confidently stage 
a patient as node negative.  In light of this, revision of the national twelve 
node guidance for lymph node harvesting following colorectal cancer surgery 
to a higher harvest level is suggested.  In Dukes’ C (node positive) colorectal 
cancer, lymph node ratio independently predicted survival and should be 
considered in future staging systems.  This may, in the future, allow tailored 
adjuvant treatment for those patients at highest risk of recurrent disease.    
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4.1  Overall Discussion and Recommendations 
 
This thesis has studied lymph node harvest in colorectal cancer resection, the 
chapters within have focused on and the factors than influence lymph node 
retrieval, intra-unit comparative audit and the impact that audit against 
national guidelines has on national nodal harvests and finally the importance 
of lymph node harvest on survival and prediction of prognosis in patients with 
colorectal cancer.  
 
 
4.2  Discussion of methodology used in this thesis 
 
This thesis used data from unit and national databases, the findings exemplify 
the strengths and weaknesses of research performed in this way; in chapter 
one access to local patient records and hospital electronic pathological 
systems, at a unit level, allowed complete data capture and accuracy. 
However, the smaller sample size of patients studied may have caused the 
null hypothesis to be rejected in some calculations when a larger study 
population may have found a statistical difference, a type II error.  The use of 
locally collected data in chapter one also allowed the study of individual 
surgeon and pathologist performance, which is not possible with national data 
as this is analysed on a unit rather than individual clinician basis.  In chapters 
two and three, use of national databases has allowed large numbers of 
patients to be studied but missing data and inaccuracies in data submitted 
may have potentially weakened the findings of these chapters.  Ideally it 
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would be possible to have complete data capture at a national level.  
Electronic central submission of pathology reports directly into CANISC, at the 
time of specimen reporting, is planned in Wales in the near future and this will 
hopefully culminate in complete data capture for future study. 
 
4.3  Factors that influence lymph node retrieval 
 
This thesis has found reporting pathologist, unit of operation, type of operation 
and more pathologically advanced tumours independently influence the 
number of nodes harvested.  The impact of reporting pathologist on nodal 
yields raises questions about the use of lymph node harvest as a marker of 
surgical quality. Whist this thesis found no difference in harvests between 
surgeons, it must be acknowledged that the radicality of surgery will 
undoubtedly impact on nodal yields and similar study in different units may 
demonstrate this. Thus, lymph node harvesting as a marker of combined 
surgical and pathological quality, but not surgical quality in isolation, has merit 
and can be recommended by the results presented in this thesis.  
 
In section A of chapter one of this thesis, surgery for colonic cancers was 
associated with higher lymph node harvests than after rectal resection, 
particularly if pre-operative neo-adjuvant radiotherapy was administered.  
These findings are in agreement with the majority of the published literature 
on the subject.  National guidelines for harvest after colorectal resection do 
not make any allowance for tumour site, given the findings in this thesis and of 
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previous work; it is a recommendation of this thesis that future guidance of 
nodal harvest should make allowance for tumour site.  
 
Ultimately, the nodal harvest for any one individual patient will be dependent 
on several factors; the performance of the surgeon and pathologist and 
variables that relate to the patient and their tumour biology.  When auditing 
the performance of surgeon and the pathologist, the variability in patient 
related variables needs to be allowed for using methods of risk adjustment. 
 
4.4  Audit 
 
This thesis has used the ACPGBI lymph node harvesting model to perform 
risk adjusted comparative audit of unit, individual pathologist and surgeon 
performance.  Risk adjustment is important for any comparative audit of 
surgical performance because of the impact case mix can have on results, for 
instance a colorectal surgeon specialising in locally advanced rectal cancer 
resection would be expected to perform a higher proportion of post long-
course APER operations, which according to the ACPGBI lymph node 
harvesting model and most published data would be expected to confer a 
lower harvest.  Risk adjustment using the ACPGBI model makes allowance 
for these differences in case mix.  However, the data in this thesis suggests 
that ACPGBI model is currently calibrated too low and needs re-calibration to 
a higher level. 
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Data from the Welsh Bowel Cancer Audit (WBCA) in chapter two, 
demonstrated the power of national guidelines and national audit to improve 
unit performance.  The WBCA reports outcomes at a unit rather individual 
clinician level.  The results of ‘in-house’ audit presented in chapter one, 
suggest that all units should audit individual members of their MDT.  This may 
be of particular benefit to the small number of units in Wales who are yet to 
comply with the national guidance for lymph node harvest.  It is therefore a 
recommendation of this thesis that all units should perform ‘in-house’ risk 
adjusted audit of the lymph node harvest of individual surgeons and 
pathologists and continue their participation in national audits.  
 
4.5  The importance of lymph node harvest and ratio on survival  
 
This thesis found that the number of lymph nodes harvested in node negative 
colorectal cancer impacts on a patients chance of survival; patients staged as 
node negative following examination of less nodes (up to a level of 15 nodes) 
had a 10-15% survival disadvantage compared to their counterparts who were 
staged as node negative following examination of more nodes.  This finding 
suggests that at least 15 nodes should be examined in patients staged as 
node negative in order to minimise the risk of under staging a patient’s 
disease. 
 
National agencies currently recommend that at least twelve nodes should be 
examined following colorectal resection.  Chapter three of this thesis found a 
survival difference of 14 % (56% vs. 70%) in patients staged as node negative 
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following examination of <12 and >12 nodes.  This finding provides further 
support for the above recommendation that targets for nodal harvest need to 
be raised.   In a patient initially staged as node negative following examination 
of less than 12 nodes, it is recommended that re-examination of the submitted 
specimen to increase nodal yield is appropriate.  If the harvest remains less 
than 12 nodes consideration should be given to offering the patient adjuvant 
chemotherapy, even in the absence of other poor prognostic features. 
 
The survival differences according to lymph node ratio (LNR) reported in 
chapter three suggests and that LNR may be a more sensitive prognostic 
indicator than the current lymph nodal staging systems.  It is therefore a 
recommendation of this thesis that LNR should be considered for inclusion in 
future staging systems for colorectal cancer.  The poorer survival experienced 
by patients with higher LNR suggests that these patients should be targeted 
for more aggressive chemotherapy regimens.  
 
 
4.6  Conclusions 
 
This thesis has demonstrated the importance of lymph node harvest following 
surgical resection for colorectal cancer.  It has confirmed that surgical, 
pathological and patient related variables impact on nodal harvest.  In house 
unit audit of individual clinicians is important and national audit against 
national guidelines are a powerful tool to improve performance.   
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5.1 Recommendations for future work 
 
 The exceptional lymph node harvests achieved by the pathologist with 
a special interest in rectal cancer specimen reporting in chapter one, 
section B is worthy of further study.  Examination of the factors that 
influence nodal retrieval in ‘their hands’ would allow study without 
pathologist as a variable, on the assumption that nodal harvest has 
been optimised by this individuals performance.  
 
 Ex-vivo sentinel node examination of colorectal cancer specimens 
appears to have promise and is worthy of further study.  In particular, 
using this technique to ultra-stage the sentinel node/s with 
immunohistochemical or molecular techniques could upstage tumours 
currently assigned a node negative status.  
 
 Further study of patients assigned a node negative stage following a 
low lymph node harvest could be performed, to calculate the impact 
that other poor prognostic features such as extra-mural vascular 
invasion, poor tumour differentiation, mucinous tumour type or serosal 
involvement have on survival.  This data could then be used to produce 
a risk model that calculates the risk of disease recurrence based on the 
presence or absence of these variables.  This would allow an informed 
decision to be made about the use of adjuvant chemotherapy in this 
setting, allowing for the risk / benefit ratio of this treatment.     
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Appendix  1 - Modified Dukes’ Classification used in this thesis[5]  
 
 
Dukes’ A: Tumour limited to the bowel wall, lymph nodes negative 
Dukes’ B: Tumour spread beyond the muscularis propria, lymph nodes 
negative 
Dukes’ C1: Lymph nodes positive by highest node spared 
Dukes’ C2: Highest lymph node involved 
Dukes’ D: Distant metastases 
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Appendix 2 UICC TNM Classification of colorectal tumours [3]  
 
pT  Primary tumour  
 
pTX  Primary tumour cannot be assessed  
pT0  No evidence of primary tumour  
pT1  Tumour invades submucosa  
pT2  Tumour invades muscularis propria  
pT3  Tumour invades through muscularis propria into subserosa or non- 
         peritonealised pericolic or perirectal tissues  
pT4  Tumour directly invades other organs (pT4a) and/or involves the visceral  
         Peritoneum (pT4b)  
  
pN  Regional lymph nodes  
 
pNX  Regional lymph nodes cannot be assessed  
pN0  No regional lymph node metastasis  
pN1  Metastasis in 1 to 3 regional lymph nodes  
pN2  Metastasis in 4 or more regional lymph nodes  
  
pN  Distant metastasis 
  
pMX Distant metastasis cannot be assessed  
pM0  No distant metastasis  
pM1  Distant metastasis  
 
pX  prefix denoted pathological stage. 
ypX  prefix denoted post neoadjuvant preoperative chemotherapy or 
radiotherapy 
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Appendix 3 – American Society of Anesthesiologists Scoring System  
 
I  - A normal healthy patient. 
II - A patient with mild systemic disease. 
III  - A patient with severe systemic disease. 
IV  - A patient with severe systemic disease that is a constant threat to life. 
V  - A moribund patient who is not expected to survive without the operation.
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Appendix 4 – The ACPGBI lymph node harvest model[107] 
 
 
Risk Factor 
 
 
LN 
score 
  
Total LN 
score 
 
Predicted 
LN harvest 
Age (years)   0 1 
 <20 -0.7  6.9 2 
 21-30 -1.5  11.0 3 
 31-40 -2.1  13.9 4 
 41-50 -2.7  16.1 5 
 51-60 -3.3  17.9 6 
 61-70 -3.9  19.5 7 
 71-80 -4.5  20.8 8 
 81-90 -5.1  22.0 9 
 >90 -5.7  23.0 10 
ASA grade   24.0 11 
 I & II 0  24.8 12 
 III -0.6  25.6 13 
 IV & V -1.0  26.4 14 
Operative urgency   27.1 15 
 Elective 0  27.7 16 
 Urgent -0.4  28.3 17 
 Emergency -1.3  28.9 18 
Dukes’ stage   29.4 19 
 A 0  30.0 20 
 B 2.6  30.4 21 
 C1 2.8  30.9 22 
 C2 4.5    
 D 2.5    
Type of surgery     
 Right / Ext R hemicolectomy 0    
 Subtotal colectomy 0.3    
 Transverse colectomy -4.5    
 Left hemicolectomy -1.8    
 Sigmoid colectomy -1.9    
 Hartmann’s procedure     
   without pre-op radiotherapy -2.2    
   with pre-op radiotherapy -3.8    
 Anterior resection     
   without pre-op radiotherapy -1.0    
   with pre-op radiotherapy -2.6    
 AP excision rectum     
   without pre-op radiotherapy -1.7    
   with pre-op radiotherapy -5.4    
Constant  26.3    
ACPGBI lymph node score  
      = 26.3 – sum lymph node score 
    
 147 
Appendix 5 – Demonstration of the use of the ACPGBI lymph node 
harvesting model to predict harvest 
1. The model is found at www.riskprediction.org.uk, the variables for the 
patient are entered into the model, as shown. 
 
2. The model calculates a predicted harvest for that individual patient 
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